

Published in final edited form as:

J Org Chem. 2007 August 17; 72(17): 6409–6420. doi:10.1021/jo070585g.

Multi-Component One-pot Synthesis of the Tumor-Associated Carbohydrate Antigen Globo-H Based on Pre-activation of Thioglycosyl Donors

Zhen Wang[†], Luyuan Zhou[†], Kheireddine El-Boubbou[†], Xin-shan Ye[§], and Xuefei Huang^{†*}

[†]*Department of Chemistry, The University of Toledo, 2801 W. Bancroft Street, MS Toledo, Ohio 43606*

[§]*The State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xue Yuan Rd. 38, Beijing 100083, China*

Abstract

Two efficient routes for rapid assembly of the tumor-associated carbohydrate antigen Globo-H hexasaccharide **2** by the pre-activation based iterative one pot strategy are reported. The first method involves the sequential coupling of four glycosyl building blocks, leading to the desired hexasaccharide in 47% overall yield in one-pot. Although model study on constructing the challenging Gal- α -1,4-Gal linkage in Gb3 trisaccharide yielded the desired α linkage almost exclusively, similar approach to assemble the hexasaccharide led to formation of significant amount of β anomer. As an alternative, the second synthesis utilizes three components in one pot with the Gal- α -1,4-Gal linkage pre-formed, producing the desired hexasaccharide in a similar overall yield as the four component approach. Both methods demonstrate that oligosaccharides containing α and β linkages within the same molecule can be constructed in one pot via the pre-activation based approach with higher glyco-assembly efficiencies than the automated solid phase synthesis strategy. Furthermore, because glycosylations can be carried out independent of anomeric reactivities of donors, it is not necessary to differentiate anomeric reactivities of building blocks through extensive protective group adjustment for chemoselective glycosylation. This confers great flexibilities in building block design allowing matching of the donor with the acceptor leading to improved overall yield.

Introduction


Globo-H **1**, a member of the globo series glycolipids, is found over-expressed on many types of human cancer cells including breast cancer, prostate cancer, ovarian cancer and lung carcinomas.^{1–5} As a distinct tumor-associated antigenic marker, Globo-H has been conjugated to an immunogenic protein carrier, which is effective in generating protective antibodies against cancer cells. Such a construct has shown promising results in clinical trials as an anti-breast cancer vaccine.^{6–9}

Due to its biological significance, Globo-H has attracted considerable attention from the synthetic community. It was first assembled by Danishefsky and coworkers using the glycal strategy,^{10,11} which was subsequently refined.¹² Other elegant syntheses include Schmidt's trichloroacetimidate method,¹³ Boon's two-directional glycosylation,¹⁴ reactivity based one-pot method by Wong and coworkers,^{15–17} linear synthesis¹⁸ and automated solid phase synthesis¹⁹ by the Seeberger group, as well as syntheses of the non-reducing end fragments.

Xuefei.huang@utoledo.edu.

^{20,21} However, many of the reported methods required various synthetic transformations of the oligosaccharide intermediates. Furthermore, with both α and β linkages in Globo-H, stereochemical control often became a formidable challenge.^{10,14,18} Therefore, a highly efficient assembly of the Globo-H hexasaccharide is still in great demand.

We have previously developed a pre-activation based iterative one-pot strategy^{22–24} for construction of complex oligosaccharides. One-pot synthesis refers to the glycosylation processes where multiple step glycosylation reactions can be performed in a single reaction flask without synthetic manipulation and purification of intermediate oligosaccharides, thus overcoming a major hurdle in the conventional stepwise chemical synthesis.²⁵ For a high-yielding one-pot reaction, glycosyl donors and acceptors must be well differentiated, allowing selective donor activation and subsequent glycosylation of the acceptor. This is traditionally accomplished by using building blocks containing different types of activatable aglycons (selective activation),^{26,27} or carrying out glycosylations in the order of decreasing anomeric reactivities of glycosyl donors (reactivity-based armed-disarmed approach),^{28,29} or a combination of both strategies.^{30,31} Besides the integration of several glycosylation processes into a single synthetic operation to furnish the target oligosaccharide in a few hours, the advantages of our pre-activation based one-pot approach are 1) only one type of glycosyl donors, i.e., *p*-tolyl thioglycosides are used, thus simplifying the synthetic design; and 2) the pre-activation approach allows us to perform glycosylations without the need to follow decreasing anomeric reactivities of donors, thus granting us much freedom in choosing protective groups to match donors and acceptors.^{23,32,33} As part of the program towards establishing the scope of our method, we explored the synthesis of Globo-H **2** containing both α and β linkages by the pre-activation based multi-component one-pot strategy.




Results and Discussion

Retrosynthetically, we divided Globo-H into four fragments, **A**, **BC**, **D** and **EF**. Although the exclusive α linkage between **A** and **B** units can be produced according to our previous studies,²⁴ an α/β mixture will be formed between the newly formed **AB** disaccharide and **C** due to the lack of neighboring group participation.¹⁴ In order to circumvent this difficulty, **BC** disaccharide will be prepared in advance with the desired β linkage. An aminopropyl spacer will be introduced to the reducing end of Globo-H **2**, which can be used for future conjugation to an immunogenic carrier protein.^{8,34}

The assembly of **BC** disaccharide was examined first using several easily prepared glycosyl donor-acceptor pairs and the results are summarized in Table 1. Each glycosylation was carried out by pre-activating the glycosyl donor³⁵ in mixed solvents of dichloromethane and diethyl ether using the promoter *p*-TolSOTf, formed *in situ* by reaction of *p*-TolSCl with AgOTf at

–78 °C,³⁶ followed by addition of the acceptor.²⁴ Reaction of **3**³⁷ and **4**³⁷ was attempted without success with recovery of acceptor **4** (Table 1, entry 1). Removal of benzylidene in donor **3** and replacing the levulinoyl with benzoyl group led to small improvements with recovery of most acceptors (entries 2,3). We investigated next the effect of substituting the bulky phthalimide (Phth) on the acceptor with more sterically accessible trichloroethoxy carbonyl (Troc) and azido moieties. While the Troc group did not have a significant effect (entry 4), glycosylation of azido containing acceptor **6** by donor **8** produced disaccharide **12β** (¹H-NMR: δ_{H1'} = 4.79 ppm, ³J_{H1',H2'} = 7.8 Hz) in 50–70% yield along with 10–20% **12α** (¹H-NMR: δ_{H1'} = 5.57 ppm, ³J_{H1',H2'} = 4.2 Hz) (entry 5). The structure of **12α** was confirmed by the presence of Bz carbonyl in the ¹³C-NMR spectrum with a chemical shift of δ_{Bz} = 166.5 ppm, ¹J_{C1'-H1'} = 174 Hz indicating α linkage,³⁸ and a HMBC correlation between C_{1'} and H₃. The erosion of stereochemical control despite the presence of participating benzoyl group on C₂ of the donor is presumably due to the competing α-directing effect of ethereal solvents.^{22,39–44} We found that by substituting diethyl ether with small amount of acetonitrile to dissolve AgOTf, the formation of disaccharide **12α** can be suppressed to negligible amount with 72% yield of the desired β disaccharide **12β** (entry 6). The enhancement of stereoselectivity is most likely due to the exclusion of diethyl ether from the reaction and/or the β directing effect of acetonitrile.⁴⁵ The disaccharide **12β** was then converted to **13** through standard transformations with an 85% overall yield (Scheme 1a). The Troc group was introduced to direct the 1,2-*trans* linkage in future glycosylation.



The introduction of the α-(1–4)-linkage at the **DE** junction of Globo-H is challenging due to the low reactivity of the axial 4-hydroxyl group of the **E** ring and the difficulty in stereochemical control. As a model, we explored first the formation of DEF trisaccharide, known as Gb3 or Pk trisaccharide, which is also highly enriched on the surface a variety of cancer cells and involved in many carbohydrate-receptor recognition events.⁴⁶ Many types of glycosyl donors, including fluoride,^{11,12} chloride,⁴⁶ trichloroacetimidate,^{18,19,47} phosphite,⁴⁸ phosphate,^{18,19} thioglycoside,^{49–51} sulfoxide⁵² and thioimidates⁵³ have been examined in this reaction. The yield for formation of the Gal-α-(1–4)-Gal linkage is often not high with anomeric mixture of products.^{11,18,19,48,50} To test whether our glycosylation condition is suitable to construct this key linkage, we examined the glycosylation of lactoside **15** by thiogalactosyl donor **14** (Scheme 1b). Without any optimization, the desired trisaccharide **16** was obtained in 82% yield with only trace amount of the β anomer isolated. The α stereochemistry of the newly formed glycosidic linkage in **16** was confirmed by NMR (¹J_{C1'-H1'} = 174 Hz).³⁸ Encouraged by this result, we decided to test the possibility of assembling Globo-H using a four component one pot reactions with building blocks **18**, **13**, **19** and **15**.


Pre-activation of the fucosyl donor **18** at –78 °C with *p*-TolSCI/AgOTf was followed by addition of the first acceptor **13** (Scheme 2a). A sterically hindered base, 2,4,6-tri-*tert*-butylpyrimidine (TTBP)⁵⁴ was added with the acceptor to neutralize trifluoromethane sulfonic acid

generated from glycosylation. The reaction temperature was raised to $-20\text{ }^{\circ}\text{C}$, and the acceptor **13** was completely consumed as judged by TLC analysis. The reaction temperature was cooled back down to $-78\text{ }^{\circ}\text{C}$, followed by sequential addition of AgOTf, *p*-TolSCl, the second acceptor galactoside **19**, TTBP and warming up to $-20\text{ }^{\circ}\text{C}$. After **19** completely disappeared, the reaction temperature was lowered to $-78\text{ }^{\circ}\text{C}$ again, and the last acceptor lactoside **15**, TTBP, AgOTf, *p*-TolSCl were added to the reaction medium. The fully protected Globo-H hexasaccharide **20a** were obtained in 47% yield from the four component one-pot reactions within seven hours, which was fully characterized by $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, gCOSY, gHMQC, gHMBC and HRMS. In addition, the anomer **20b** was also produced in 23% yield.⁵⁵ Both Globo-H anomers will be useful for immunological studies as demonstrated by Danishefsky and coworkers.¹⁰ It is noteworthy that thiogalactoside **19** has higher anomeric reactivity than disaccharide **13**. This reversal of anomeric reactivity, i.e., a more reactive thioglycosyl acceptor is glycosylated by a less reactive thioglycosyl donor, is not possible with the reactivity based chemoselective glycosylation method.^{28,29,37} The pre-activation method allowed us to use the readily available building block **19** instead of going through elaborate protective group manipulations to achieve the precise anomeric reactivity.¹⁵⁻¹⁷

Recently, Seeberger and coworkers have reported an elegant synthesis of Globo-H hexasaccharide¹⁹ with an overall yield of 30% for glyco-assembly using the automated solid phase synthesis pioneered by their group.⁵⁶ Compared to the automated method, our synthesis of the desired Globo-H hexasaccharide achieved higher glyco-assembly yield in shorted time without consuming large excess of precious glycosyl building blocks. This underscores the advantage of the pre-activation based iterative one pot oligosaccharide synthesis method.

Deprotection of the hexasaccharide **20a** was performed by first removing the Troc protecting group with 1 M NaOH in THF followed by acetylation. Staudinger reduction of the azide group and subsequent catalytic hydrogenation over Pearlman's catalyst⁵⁷ gave the fully deprotected Globo-H **2** in 50% overall yield for all deprotection steps (Scheme 2b). Attempts to reduce the azide and remove benzyl groups simultaneously by hydrogenation failed even in the presence of additives such as di-*t*-butyl carbonate⁵⁸ and hydrochloric acid.

The formation of **20b** in the 4+2 glycosylation is surprising in view of our model studies on Gb3. Moreover, previous syntheses of Globo-H hexasaccharides through the 4+2 coupling of tetrasaccharide donors with lactoside acceptors by the Wong group¹⁷ and the Schmidt group¹³ did not report any stereoisomers being formed. This unpredicted discrepancy highlights the challenge of complex oligosaccharide assembly. The generation of **20b** may be due to the increased size of the tetrasaccharide donor in our 4+2 coupling as compared to donor **14**. We tested next the lactoside acceptor **21** containing multiple electron withdrawing benzoyl groups in the 4+2 glycosylation reaction, as the less reactive acceptor is expected to be more selective. However, the glycosylation yield was low with large amount of acceptor recovered.



Since trisaccharide **16** was synthesized highly stereoselectively, as an alternative to the four component one-pot strategy, we examined a three component approach with the challenging Gal- α -1,4-Gal linkage preformed. The *p*-methoxybenzyl moiety in trisaccharide **16** was selectively removed to generate acceptor **17** in 80% yield (Scheme 1b). One-pot sequential

glycosylation of fucoside **18** with disaccharide **13** and trisaccharide **17** produced hexasaccharide **20a** with a 74% overall yield (Scheme 3), which was identical in all aspects to **20a** prepared via the four component approach thus further confirming our stereochemical assignment. Starting from monosaccharide and disaccharide building blocks, the overall yield for **20a** through the three component approach is similar to that of the four component route.

Conclusions

We have developed two routes for rapid assembly of the tumor-associated carbohydrate antigen Globo-H hexasaccharide **2** by the pre-activation based one pot strategy, demonstrating that oligosaccharides containing α and β linkages within the same molecule can be constructed in one pot. Higher glyco-assembly efficiencies have been achieved with only near stoichiometric amount of building blocks via the pre-activation based one-pot method as compared to the automated solid phase synthesis method. However, reliable stereochemical control in glycosylation still remains a challenge, which will require further developments and studies.

Experimental Section

Characterization of anomeric stereochemistry

The stereochemistries of the newly formed glycosidic linkages in Globo-H hexasaccharides and intermediates are determined by $^3J_{\text{H1,H2}}$ through $^1\text{H-NMR}$ and/or $^1J_{\text{C1,H1}}$ through gHMQC 2-D NMR (without ^1H decoupling). Smaller coupling constants of $^3J_{\text{H1,H2}}$ (around 3 Hz) indicate α linkages and larger coupling constants $^3J_{\text{H1,H2}}$ (7.2 Hz or larger) indicate β linkages. This can be further confirmed by $^1J_{\text{C1,H1}}$ (~170 Hz) for α linkages and $^1J_{\text{C1,H1}}$ (~160 Hz) for β linkages.³⁸

p-Tolyl 2-azido-4,6-*O*-benzylidene-2-deoxy-1-thio- β -*D*-galactopyranoside (**6**)

Trichloroethoxycarbonyl chloride (7.7 mL, 57.2 mmol) was added dropwise over a period of 30 minutes at room temperature to a vigorously stirred solution of *D*-galactosamine hydrochloride (10 g, 46.3 mmol) and NaHCO_3 (11.8 g, 139.9 mmol) in water (90 mL). The mixture was stirred for another 2 hours and then filtered to give a yellowish solid, which was dried under vacuum. The obtained crude solid (15 g) was dissolved in pyridine (50 mL) and then acetic anhydride (30 mL) was added at 0 °C over a period of 30 minutes. The mixture was stirred at room temperature under N_2 overnight and then quenched with ethanol (20 mL) at 0 °C. The mixture was concentrated and the resulting residue was diluted with ethyl acetate and washed with saturated aqueous solution of NaHCO_3 , 10 % HCl, water, and brine. The organic phase was dried over Na_2SO_4 , filtered and concentrated. Without separation, the obtained crude solid (21 g) and *p*-toluenethiol (5.76 g, 46.3 mmol) were dissolved in CH_2Cl_2 (60 mL) and the solution was cooled to 0 °C. Boron trifluoride etherate (17.8 mL, 160 mmol) was added dropwise at 0 °C and the mixture was stirred under N_2 at room temperature for 6 h. The mixture was diluted with CH_2Cl_2 (400 mL) and washed with saturated aqueous solution of NaHCO_3 until the pH is 7 and then dried over Na_2SO_4 , filtered and concentrated. The obtained crude product was recrystallized from EtOAc/hexanes to afford compound *p*-tolyl 3,4,6-tri-*O*-acetyl-2-deoxy-2-*N*-trichloroethoxycarbonylamino-1-thio- β -*D*-galactopyranoside⁵⁹ (**S1**) as white solid (20.67 g, 76% for three steps). $^1\text{H-NMR}$ (600 MHz, CDCl_3): δ 1.98, 2.04, 2.13 (3s, 9H, 3 \times COCH_3), 2.34 (s, 3H, SPhCH_3), 3.91–3.95 (m, 2H, H-2, H-5), 4.10–4.20 (m, 2H, H-6a, H-6b), 4.73–4.80 (m, 2H, CH_2CCl_3), 4.84 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 5.19 (dd, 1H, $J_{2,3} = 10.8$ Hz, $J_{3,4} = 2.4$ Hz, H-3), 5.30 (d, 1H, $J_{\text{NH},2} = 9.6$ Hz, NH), 5.39 (d, 1H, $J_{3,4} = 2.4$ Hz, H-4), 7.10–7.16 (m, 2H), 7.40–7.46 (m, 2H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ 20.9, 20.9, 21.4, 51.4, 62.0, 67.1, 71.2, 74.6, 74.7, 87.8, 95.7, 129.9, 133.3, 138.7, 154.3, 170.5, 170.7, 170.8. ESI-MS $[\text{M}+\text{Na}]^+$ $\text{C}_{22}\text{H}_{26}\text{NaCl}_3\text{NO}_9\text{S}$ calcd 608.0, obsd 608.3. *p*-Tolyl 3,4,6-tri-*O*-acetyl-2-deoxy-2-*N*-trichloroethoxycarbonylamino-1-thio- β -*D*-galactopyranoside **S1** (3 g, 5.1 mmol)

was dissolved in MeOH (12 mL), AcOH (6 mL) and CH₂Cl₂ (6 mL). Zn powder (6 g, 92 mmol) was added slowly at 0 °C and the mixture was stirred under N₂ at room temperature for 1 hour. The mixture was filtered and concentrated to dryness. The resulting residue was diluted with CH₂Cl₂ (200 mL) and washed with saturated aqueous solution of NaHCO₃ until the pH is 7 and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (EtOAc) afforded *p*-tolyl 3,4,6-tri-*O*-acetyl-2-amino-2-deoxy-1-thio-β-*D*-galactopyranoside as white solid (S2) (1.8 g, 85.7%). ¹H-NMR (400 MHz, CDCl₃): δ 2.02, 2.05, 2.09 (3s, 9H, 3 × COCH₃), 2.35 (s, 3H, SPhCH₃), 3.18 (t, 1H, *J* = 10.0 Hz, H-2), 3.91 (t, 1H, *J* = 6.2 Hz, H-5), 4.11 (dd, 1H, *J* = 6.2, 10.8 Hz, H-6a), 4.18 (dd, 1H, *J* = 6.2, 10.8 Hz, H-6b), 4.49 (d, 1H, *J*_{1,2} = 10.0 Hz, H-1), 4.78 (dd, 1H, *J*_{2,3} = 10.0 Hz, *J*_{3,4} = 3.2 Hz, H-3), 5.36 (d, 1H, *J*_{3,4} = 3.2 Hz, H-4), 7.10–7.18 (m, 2H), 7.44–7.50 (m, 2H); ¹³C-NMR (100 MHz, CDCl₃): δ 20.8, 20.9, 20.9, 21.4, 49.9, 62.0, 66.8, 74.4, 75.2, 90.4, 128.4, 129.9, 133.3, 138.6, 170.4, 170.5, 170.7. ESI-MS [M+H]⁺ C₁₉H₂₆NO₇S calcd 412.1, obsd 412.1. *p*-Tolyl 3,4,6-tri-*O*-acetyl-2-amino-2-deoxy-1-thio-β-*D*-galactopyranoside S2 (1.8 g, 4.37 mmol, 1 equiv) was dissolved in MeOH (7.5 mL) and CH₂Cl₂ (7.5 mL). 1 M NaOMe (2.2 mL, 2.2 mmol) was added and the mixture was stirred at room temperature for 2 h. The mixture was neutralized by conc. HCl until the pH is around 7 and then concentrated and dried under vacuum. The resulting residue, K₂CO₃ (1.5g, 10.87 mmol) and catalytic amount of ZnCl₂ (40 mg, 0.3 mmol) were dissolved in MeOH (12 mL) and H₂O (3 mL). Freshly prepared TfN₃⁶⁰ (13 mL in CH₂Cl₂, 13.1 mmol) was added and the mixture was stirred at room temperature overnight. The solvent was evaporated and the resulting residue was diluted with EtOAc (100 mL). The mixture was neutralized by conc. HCl until the pH value is 6–7 and then concentrated to dryness. Silica gel column chromatography (9:1 CH₂Cl₂–MeOH) afforded *p*-tolyl 2-azido-2-deoxy-1-thio-β-*D*-galactopyranoside⁶¹ (S3) as a white solid (1.2 g, 88%). ¹H-NMR (600 MHz, CD₃OD): δ 2.22 (s, 3H, SPhCH₃), 3.37 (t, 1H, *J* = 9.6 Hz, H-2), 3.39–3.40 (m, 2H, H-3, H-5), 3.58–3.68 (m, 2H, H-6a, H-6b), 3.74 (d, 1H, *J*_{3,4} = 2.4 Hz, H-4), 4.34 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 7.01–7.06 (m, 2H), 7.33–7.40 (m, 2H); ¹³C-NMR (100 MHz, CD₃OD): δ 21.3, 62.7, 64.6, 69.8, 75.4, 80.8, 88.5, 130.7, 130.8, 130.9, 133.9, 134.0, 139.3. ESI-MS [M+Na]⁺ C₁₃H₁₇NaN₃O₄S calcd 334.1, obsd 334.3. The mixture of compound *p*-tolyl 2-azido-2-deoxy-1-thio-β-*D*-galactopyranoside S3 (1.2 g, 3.85 mmol), camphorsulfonic acid (0.27 g, 1.16 mmol) and benzaldehyde dimethylacetal (0.7 mL, 4.62 mmol) in toluene (20 mL) was stirred at room temperature for 1 h and then diluted with EtOAc (200 mL). The mixture was washed with saturated aqueous solution of NaHCO₃, water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound **6** as white solid (1.15 g, 75%). [α]_D²⁰ –31.9 (*c* = 1, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 2.36 (s, 3H, SPhCH₃), 2.62 (d, 1H, *J*_{3,3-OH} = 10.2 Hz, OH), 3.45 (s, 1H, H-5), 3.47 (t, 1H, *J* = 10.2 Hz, H-2), 3.59 (dt, 1H, *J*_{3,4} = 3.0 Hz, *J*_{2,3} = 10.2, *J*_{3,3-OH} = 10.2 Hz, H-3), 3.99 (dd, 1H, *J* = 1.8, 12.6 Hz, H-6a), 4.12 (d, 1H, *J*_{3,4} = 3.0 Hz, H-4), 4.35 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 4.37 (dd, 1H, *J* = 1.8, 12.6 Hz, H-6b), 5.49 (s, 1H, CHPh), 7.11–7.12 (d, 2H, *J* = 7.8 Hz, aromatic), 7.35–7.41 (m, 5H, aromatic), 7.59–7.66 (m, 2H), ¹³C-NMR (150 MHz, CDCl₃): δ 21.6, 62.2, 69.5, 69.96, 70.00, 73.4, 74.6, 74.7, 85.2, 101.6, 101.7, 126.5, 126.8, 128.5, 129.7, 130.1, 135.0, 137.6, 139.0. ESI-MS [M+Na]⁺ C₂₀H₂₁NaO₄S calcd 422.1, obsd 422.2; Comparison of the NMR data with those reported in the literature³⁷ confirmed the identity of **6**.

***p*-Tolyl 2-*O*-benzoyl-3,4,6-tri-*O*-benzyl-1-thio-β-*D*-galactopyranoside (8)**

β-*D*-Galactopyranosyl pentaacetate (10 g, 25.6 mmol) was dissolved in HBr in acetic acid (30 mL, 33% w/w, 173.6 mmol). After 6 hours, the mixture was diluted with CH₂Cl₂ (240 mL) and poured into crushed ice in saturated NaHCO₃ (600 mL). The organic phase was separated and washed again with saturated NaHCO₃ until the pH was about 7 and then dried over Na₂SO₄, filtered and concentrated. The resulting residue, 2,6-lutidine (11.93 mL, 102.4 mmol) and Bu₄NBr (3.3 g, 10.24 mmol) were dissolved in CH₂Cl₂ (45 mL) and dry EtOH (8.5 mL, 6 equiv.). The mixture was stirred at room temperature under N₂ overnight and then

concentrated and vacuum dried to afford colorless oil (10g). The obtained oil was dissolved in a mixture of CH₂Cl₂/MeOH (50 mL each) and 1 M solution of NaOMe (25.6 mL, 25.6 mmol) was added at room temperature. The mixture was stirred for 2 h at room temperature under N₂ and then concentrated and vacuum dried. The obtained residue was dissolved in DMF (100 mL) and the solution was cooled to 0 °C. NaH (4 g, 60% NaH in mineral oil, 100 mmol) was added in portions, followed by addition of BnBr (15 mL, 125 mmol). The mixture was stirred at room temperature under N₂ for 4 hours and then diluted with EtOAc (300 mL). The mixture was washed with saturated NaHCO₃, water and then dried over Na₂SO₄, filtered and concentrated. The resulting residue (8.5 g), *p*-toluenethiol (6.7 g, 53.9 mmol) and HgBr₂ (0.46 g, 1.28 mmol) were put into CH₃CN (20 mL) and the mixture was heated at 60 °C under N₂ overnight. The solvent was evaporated and then the residue was diluted with CH₂Cl₂ (300 mL). The mixture was washed with saturated NaHCO₃, water and 10 % HCl and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound *p*-tolyl 2-*O*-acetyl-3,4,6-tri-*O*-benzyl-1-thio-β-D-galactopyranoside⁶² (S4) as white solid (6.4 g, 42% for 5 steps). ¹H-NMR (600 MHz, CDCl₃): δ 2.04 (s, 3H, COCH₃), 2.29 (s, 3H, SPhCH₃), 3.54 (dd, 1H, *J*_{2,3} = 9.6 Hz, *J*_{3,4} = 3.0 Hz, H-3), 3.59–3.67 (m, 3H, H-5, H-6a, H-6b), 3.97 (d, 1H, *J*_{3,4} = 3.0 Hz, H-4), 4.41, 4.45, 4.52, 4.56 (4d, 4H, *J* = 12.0 Hz, CH₂Ph), 4.55 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 4.66 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 4.93 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 5.39 (t, 1H, *J* = 9.6 Hz, H-2), 6.98–7.06 (m, 2H), 7.25–7.34 (m, 15H, aromatic), 7.37–7.38 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.3, 21.4, 69.0, 70.0, 72.2, 73.0, 73.8, 74.6, 77.8, 81.7, 87.3, 127.67, 127.70, 127.99, 128.03, 128.1, 128.2, 128.4, 128.6, 129.7, 130.0, 132.7, 137.8, 138.09, 138.12, 138.7, 169.7. ESI-MS [M+Na]⁺ C₃₆H₃₈NaO₆S calcd 621.2, obsd 621.5. *p*-Tolyl 2-*O*-acetyl-3,4,6-tri-*O*-benzyl-1-thio-β-D-galactopyranoside S4 (3 g, 5 mmol) was dissolved in a mixture of CH₂Cl₂/MeOH (50 mL each) and 1 M NaOMe (10 mL, 10 mmol) was added at room temperature. The mixture was stirred for 2 h at room temperature under N₂ and then was neutralized with Amberlite IR-120 until the pH is around 6–7. The mixture was concentrated and diluted with CH₂Cl₂ (300 mL) and washed with saturated NaHCO₃, 10% HCl and water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound *p*-tolyl 3,4,6-tri-*O*-benzyl-1-thio-β-D-galactopyranoside (S5) as white solid (2.56 g, 92%). ¹H-NMR (600 MHz, CDCl₃): δ 2.29 (s, 3H, SPhCH₃), 2.42 (d, 1H, *J*_{2,2-OH} = 2.4 Hz, OH), 3.46 (dd, 1H, *J*_{2,3} = 9.6 Hz, *J*_{3,4} = 2.4 Hz, H-3), 3.63–3.66 (m, 3H, H-5, H-6a, H-6b), 3.95–3.98 (m, 2H, H-2, H-4), 4.44 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 4.47 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 4.49, 4.56, 4.67, 4.73, 4.89 (5d, 5H, *J* = 12.0 Hz, CH₂Ph), 6.98–7.05 (m, 2H), 7.25–7.35 (m, 15H, aromatic), 7.44–7.45 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.4, 68.9, 69.3, 72.6, 73.5, 73.8, 74.6, 77.8, 83.4, 89.0, 127.6, 127.9, 127.95, 128.04, 128.05, 128.2, 128.4, 128.7, 128.8, 128.9, 129.8, 133.1, 138.0, 138.1, 138.3, 138.9. ESI-MS [M+Na]⁺ C₃₄H₃₆NaO₅S calcd 579.2, obsd 579.6. *p*-Tolyl 3,4,6-tri-*O*-benzyl-1-thio-β-D-galactopyranoside S5 (3.8 g, 6.8 mmol) and *N,N*-dimethylamino pyridine (DMAP) (0.08 g, 0.68 mmol) were dissolved in pyridine (20 mL) and then benzoyl chloride (2.38 mL, 20.5 mmol) was added. The mixture was stirred at room temperature under N₂ for 4 h and then diluted with CH₂Cl₂ (200 mL). The mixture was washed with saturated NaHCO₃, water and 10 % HCl and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound **8** as white solid (4.2 g, 93%). [α]_D +38.2 (*c* = 1, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 2.25 (s, 3H, SPhCH₃), 3.65–3.69 (m, 4H, H-3, H-5, H-6a, H-6b), 4.03 (d, 1H, *J*_{3,4} = 2.4 Hz, H-4), 4.41, 4.45, 4.47, 4.59, 4.61 (5d, 5H, *J* = 12.0 Hz, CH₂Ph), 4.71 (d, 1H, *J*_{1,2} = 10.2 Hz, H-1), 4.97 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 5.68 (t, 1H, *J* = 10.2 Hz, H-2), 6.96–6.97 (d, 2H, *J* = 7.8 Hz, aromatic), 7.10–7.15 (m, 5H, aromatic), 7.25–7.36 (m, 12H, aromatic), 7.41–7.42 (m, 2H, aromatic), 7.53–7.55 (m, 1H, aromatic), 8.00–8.07 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.5, 69.2, 70.8, 72.1, 73.1, 73.9, 74.7, 78.0, 81.5, 87.5, 127.8, 127.99, 128.00, 128.1, 128.2, 128.4, 128.5, 128.6, 128.7, 128.8, 129.8, 130.0, 130.2, 130.5, 133.0, 133.4, 137.9, 138.0, 138.2, 138.8, 165.6. HRMS: [M+Na]⁺ C₄₁H₄₀NaO₆S calcd 683.2443, obsd 683.2421.

General procedure for single step pre-activation based glycosylation

A solution of donor (0.060 mmol) and freshly activated molecular sieve MS 4 Å (200 mg) in CH₂Cl₂ (2 mL) was stirred at room temperature for 30 minutes, and cooled to -78 °C, which was followed by addition of AgOTf (47 mg, 0.18 mmol) dissolved in Et₂O (1 mL) without touching the wall of the flask. After 5 minutes, orange colored *p*-TolSCL (9.5 μL, 0.060 mmol) was added through a microsyringe. Since the reaction temperature was lower than the freezing point of *p*-TolSCL, *p*-TolSCL was added directly into the reaction mixture to prevent it from freezing on the flask wall. The characteristic yellow color of *p*-TolSCL in the reaction solution dissipated rapidly within a few seconds indicating depletion of *p*-TolSCL. After the donor was completely consumed according to TLC analysis (about 5 minutes at -78 °C), a solution of acceptor (0.060 mmol) in CH₂Cl₂ (0.2 mL) was slowly added dropwise via a syringe. The reaction mixture was warmed to -10 °C under stirring in 2 hours. Then the mixture was diluted with CH₂Cl₂ (20 mL) and filtered over Celite. The Celite was further washed with CH₂Cl₂ until no organic compounds were observed in the filtrate by TLC. All CH₂Cl₂ solutions were combined and washed twice with saturated aqueous solution of NaHCO₃ (20 mL) and twice with water (10 mL). The organic layer was collected and dried over Na₂SO₄. After removal of the solvent, the desired disaccharide was purified from the reaction mixture via silica gel flash chromatography.

p-Tolyl 2-*O*-benzoyl-3,4,6-tri-*O*-benzyl-β-D-galactopyranosyl-(1→3)-2-azido-4,6-*O*-benzylidene-2-deoxy-1-thio-β-D-galactopyranoside (**12β**) and *p*-tolyl 2-*O*-benzoyl-3,4,6-tri-*O*-benzyl-α-D-galactopyranosyl-(1→3)-2-azido-4,6-*O*-benzylidene-2-deoxy-1-thio-β-D-galactopyranoside (**12α**)

Compound **12β** and **12α** was synthesized from donor **8** and acceptor **6** in 50–70% and 10–20% yield respectively following the general procedure of single step glycosylation. When CH₃CN (100 μl) was used instead of diethyl ether to dissolve the AgOTf, the formation of disaccharide **12α** can be suppressed to negligible amount with 72% yield of the desired β disaccharide **12β**. For **12β**: [α]_D -28.5 (*c* = 4.3, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 2.24 (s, 3H, SPhCH₃), 3.31 (s, 1H, H-5), 3.55–3.65 (m, 6H, H-2, H-3, H-3', H-5', H-6a', H-6b'), 3.84 (d, 1H, *J* = 10.8 Hz, H-6a), 3.96 (d, 1H, *J*_{3',4'} = 2.4 Hz, H-4'), 4.24–4.27 (m, 2H, H-4, H-6b), 4.30 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 4.44–4.47 (m, 3H, CH₂Ph), 4.59–4.62 (m, 2H, *J* = 12.0 Hz, CH₂Ph), 4.79 (d, 1H, *J*_{1',2'} = 7.8 Hz, H-1'), 4.98 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 5.37 (s, 1H, CHPh), 5.62 (t, 1H, *J*_{1',2'} = 7.8 Hz, H-2'), 6.83–6.92 (m, 2H), 7.10–7.18 (m, 5H, aromatic), 7.23–7.41 (m, 17H, aromatic), 7.43–7.52 (m, 2H), 7.49–7.59 (m, 1H), 7.94–8.04 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.4, 59.7, 69.2, 69.3, 70.1, 71.7, 72.0, 72.6, 73.7, 74.2, 74.6, 74.9, 79.3, 80.3, 85.8, 100.8, 102.3, 126.2, 126.7, 127.8, 127.9, 128.0, 128.1, 128.2, 128.4, 128.5, 128.6, 128.7, 128.9, 129.9, 130.0, 130.2, 133.1, 134.5, 137.6, 137.9, 138.0, 138.5, 138.6, 165.5; HRMS: [M+Na]⁺ C₅₄H₅₃N₃NaO₁₀S calcd 958.3349, obsd 958.3365. gHMQC (without ¹H decoupling): ¹J_{C1',H1'} = 160.9 Hz, ¹J_{C1,H1} = 159.9 Hz; For **12α**: [α]_D +70.8 (*c* = 4.5, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 2.27 (s, 3H, SPhCH₃), 3.26 (s, 1H, H-5), 3.57–3.65 (m, 3H, H-3, H-6a', H-6b'), 3.79 (t, 1H, *J* = 9.6 Hz, H-2), 3.86 (d, 1H, *J* = 12.0 Hz, H-6a), 4.06 (s, 1H, H-4), 4.09 (d, 1H, *J*_{3',4'} = 2.4 Hz, H-4'), 4.17 (dd, 1H, *J*_{2',3'} = 10.8 Hz, *J*_{3',4'} = 2.4 Hz, H-3'), 4.22–4.24 (m, 2H, H-5', H-6b), 4.32 (d, 1H, *J*_{1,2} = 9.6 Hz, H-1), 4.47, 4.51, 4.59, 4.66, 4.68, 4.93 (6d, 6H, *J* = 12.0 Hz, CH₂Ph), 5.16 (s, 1H, CHPh), 5.42 (dd, 1H, *J*_{1',2'} = 3.6 Hz, *J*_{2',3'} = 10.8 Hz, H-2'), 5.57 (d, 1H, *J*_{1',2'} = 3.6 Hz, H-1'), 6.90–6.99 (m, 2H), 6.98–7.02 (m, 4H, aromatic), 7.12–7.44 (m, 19H, aromatic), 7.50–7.59 (m, 2H), 7.72–7.82 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.4, 59.6, 68.9, 69.2, 69.7, 70.0, 70.7, 71.9, 73.2, 73.4, 74.7, 75.0, 76.0, 76.9, 85.7, 93.1, 100.2, 126.1, 126.9, 127.78, 127.80, 127.82, 127.86, 127.87, 128.3, 128.45, 128.49, 128.51, 128.55, 129.68, 129.70, 129.9, 133.0, 134.3, 137.5, 138.2, 138.3, 138.4, 138.5, 166.5. ESI-MS [M+Na]⁺ C₅₄H₅₃N₃NaO₁₀S calcd 958.3, obsd 958.4. gHMQC (without ¹H decoupling): ¹J_{C1',H1'} = 172.4 Hz, ¹J_{C1,H1} = 160.1 Hz.

***p*-Tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy-1-thio- β -D-galactopyranoside (13)**

Compound **12 β** (1.7 g, 1.81 mmol) was dissolved in a mixture of CH₂Cl₂/MeOH (25 mL each) and 1 M NaOMe (5.4 mL, 5.4 mmol) was added at room temperature. The mixture was heated at reflux for 4 h under N₂ and then was neutralized with conc. HCl until the pH is around 7. The mixture was concentrated and then diluted with CH₂Cl₂ (200 mL). The organic phase was washed with saturated aqueous solution of NaHCO₃, 10% HCl and water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (3:1:1 Hexanes–EtOAc–CH₂Cl₂) afforded *p*-tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-azido-2-deoxy-1-thio- β -D-galactopyranoside (S6) as white solid (1.5 g, quantitative). ¹H-NMR (600 MHz, CDCl₃): δ 2.32 (s, 3H, SPhCH₃), 2.52 (s, 1H, OH), 3.35 (s, br, 1H, H-5), 3.46 (dd, 1H, $J_{2,3'} = 9.6$ Hz, $J_{3',4'} = 3.0$ Hz, H-3'), 3.51–3.61 (m, 4H, H-3, H-5', H-6a', H-6b'), 3.78 (dd, 1H, $J_{1,2} = 10.2$ Hz, H-2), 3.85 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4'), 3.86–3.89 (dd, 1H, $J = 1.8$, 12.0 Hz, H-6a), 3.96 (t, 1H, $J = 9.6$ Hz, H-2'), 4.22 (d, 1H, $J_{3',4'} = 3.0$ Hz, H-4), 4.31 (dd, 1H, $J = 1.8$, 12.0 Hz, H-6b), 4.35 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 4.42, 4.46 (2d, 2H, $J = 12.0$ Hz, CH₂Ph), 4.48 (d, 1H, $J_{1',2'} = 9.6$ Hz, H-1'), 4.59, 4.72, 4.77, 4.90 (4d, 4H, CH₂Ph), 5.45 (s, 1H, CHPh), 6.98–7.08 (m, 2H), 7.25–7.43 (m, 20H, aromatic), 7.58–7.68 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.5, 60.2, 69.3, 69.4, 70.3, 71.4, 73.3, 73.6, 73.7, 74.3, 74.9, 75.4, 80.4, 82.1, 85.7, 101.3, 105.4, 126.2, 127.0, 127.9, 128.98, 127.99, 128.2, 128.3, 128.5, 128.6, 128.7, 128.8, 129.3, 130.1, 135.0, 138.0, 138.1, 138.5, 138.6, 138.9; HRMS: [M+Na]⁺ C₄₇H₄₉N₃NaO₉S calcd 854.3087, obsd 854.3085. *p*-Tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-azido-2-deoxy-1-thio- β -D-galactopyranoside S6 (1.3 g, 1.56 mmol), 1,3-propanedithiol (1.57 mL, 15.6 mmol) and Et₃N (1.10 mL, 15.6 mmol) were dissolved in a mixture of CH₂Cl₂/MeOH (10 mL each). The mixture was heated at reflux overnight under N₂ and then concentrated. The resulting residue was diluted with CH₂Cl₂ (200 mL) and then washed with saturated aqueous solution of NaHCO₃ and water, dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (20:1 CH₂Cl₂–MeOH) afforded *p*-tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-amino-2-deoxy-1-thio- β -D-galactopyranoside (S7) as white solid (1.07 g, 85%). ¹H-NMR (600 MHz, CDCl₃): δ 2.32 (s, 4H, SPhCH₃, OH), 3.25 (t, 1H, $J = 9.6$ Hz, H-2), 3.37 (s, 1H, H-5), 3.37–3.39 (dd, 1H, $J_{2,3'} = 9.6$ Hz, $J_{3',4'} = 3.0$ Hz, H-3'), 3.53 (dd, 1H, $J_{2,3} = 10.2$ Hz, $J_{3,4} = 3.0$ Hz, H-3), 3.55–3.59 (m, 3H, H-5', H-6a', H-6b'), 3.86 (d, 1H, $J_{3',4'} = 3.0$ Hz, H-4'), 3.86 (d, 1H, $J = 12.0$ Hz, H-6a), 3.95 (t, 1H, $J = 9.6$ Hz, H-2'), 4.16 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4), 4.29 (d, 1H, $J = 12.0$ Hz, H-6b), 4.35 (d, 1H, $J_{1,2} = 9.6$ Hz, H-1), 4.43–4.44 (m, 3H, $J_{1',2'} = 10.2$ Hz, H-1', CH₂Ph), 4.57, 4.65, 4.68, 4.86 (4d, 4H, $J = 12.0$ Hz, CH₂Ph), 5.43 (s, 1H, CHPh), 6.95–7.08 (m, 2H), 7.23–7.42 (m, 20H, aromatic), 7.50–7.58 (m, 2H); ¹³C-NMR (100 MHz, CDCl₃): δ 21.4, 49.7, 69.0, 69.6, 70.3, 71.5, 72.7, 73.0, 73.7, 74.2, 74.7, 75.4, 82.4, 83.8, 88.4, 101.1, 106.1, 126.6, 126.9, 127.79, 127.83, 127.9, 128.0, 128.2, 128.4, 128.5, 128.66, 128.68, 129.1, 129.9, 134.3, 138.08, 138.14, 138.3, 138.5, 138.6. HRMS: [M+Na]⁺ C₄₇H₅₁NNaO₉S calcd 828.3182, obsd 828.3182. *p*-Tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-amino-2-deoxy-1-thio- β -D-galactopyranoside S7 (1.06 g, 1.31 mmol) and solid NaHCO₃ (0.22 g, 2.62 mmol) were put into THF (16 mL) and then TrocCl (0.214 mL, 1.57 mmol) was added. The mixture was stirred at room temperature under N₂ for 4 hours and filtrated. The filtrate was concentrated and then diluted with CH₂Cl₂ (100 mL). The mixture was washed with water and brine, dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound **13** as white solid (1.2 g, 93%); [α]_D –13.6 (*c* = 1, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 2.32 (s, 3H, SPhCH₃), 3.34 (d, 1H, $J_{2,3'} = 7.8$ Hz, $J_{3',4'} = 3.0$ Hz, H-3'), 3.40 (s, 1H, H-5), 3.48–3.61 (m, 3H, H-5', H-6a', H-6b'), 3.65 (dd, 1H, $J_{1,2} = 10.2$ Hz, $J_{NH,2} = 7.2$ Hz, H-2), 3.82 (d, 1H, $J_{3',4'} = 3.0$ Hz, H-4'), 3.87 (d, 1H, $J = 12.0$ Hz, H-6a), 3.92 (t, 1H, $J = 7.8$ Hz, H-2'), 4.24–4.29 (m, 3H, H-3, H-4, H-6a), 4.35 (d, 1H, $J_{1',2'} = 7.8$ Hz, H-1'), 4.46 (s, 2H, CH₂CCl₃), 4.58 (d, 1H, $J = 12.0$ Hz, CH₂Ph), 4.66–4.71 (m, 3H, $J = 12.0$ Hz,

CH₂Ph), 4.78, 4.88 (2d, 2H, $J = 12.0$ Hz, CH₂Ph), 5.07 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 5.46 (s, 1H, CHPh), 5.52 (d, 1H, $J_{NH,2} = 7.2$ Hz, NH), 7.00–7.09 (m, 2H), 7.21–7.44 (m, 20H, aromatic), 7.50–7.59 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 21.5, 51.8, 69.2, 69.5, 70.3, 71.3, 73.0, 73.4, 73.8, 74.2, 74.7, 74.8, 76.1, 77.3, 81.9, 84.3, 95.9, 101.1, 105.0, 127.0, 127.4, 127.9, 128.0, 128.0, 128.1, 128.2, 128.3, 128.5, 128.7, 128.76, 128.77, 129.2, 130.0, 134.5, 138.10, 138.12, 138.4, 138.6, 154.3; HRMS: [M+Na]⁺ C₅₀H₅₂Cl₃NNaO₁₁S calcd 1002.2224, obsd 1002.2208.

***p*-Tolyl 2,4,6-tri-*O*-benzyl-1-thio- β -D-galactopyranoside (19)**

β -D-Galactose pentaacetate (20 g, 51.2 mmol) and *p*-toluenethiol (7.3 g, 58.8 mmol) were dissolved in CH₂Cl₂ (400 mL). Boron trifluoride etherate (20.15 mL, 153.6 mmol) was added dropwise at 0 °C and the mixture was stirred under N₂ at room temperature for 20 h. The mixture was diluted with CH₂Cl₂ (450 mL) and washed with saturated NaHCO₃, dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded *p*-tolyl 2,3,4,6-tetra-*O*-acetyl-1-thio- β -D-galactopyranoside (S8) as white solid (21.2 g, 91%). ¹H-NMR (600 MHz, CDCl₃): δ 1.98, 2.05, 2.10, 2.12 (s, 12H, 4 × COCH₃), 2.35 (s, 3H, SPhCH₃), 3.92 (t, 1H, $J = 6.6$ Hz, H-5), 4.10–4.20 (m, 2H, H-6a, H-6b), 4.66 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 5.04 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 3.0$ Hz, H-3), 5.22 (t, 1H, $J = 10.2$ Hz, H-2), 5.41 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4), 7.08–7.16 (m, 2H), 7.40–7.46 (m, 2H); ¹³C-NMR (150 MHz, CDCl₃): δ 20.82, 20.86, 20.90, 21.1, 21.4, 61.8, 67.4, 67.5, 72.2, 74.5, 87.1, 128.8, 129.9, 133.3, 138.7, 160.74 169.7, 170.3, 170.4, 170.6. ESI-MS [M+Na]⁺ C₂₁H₂₆NaO₉S calcd 477.1, obsd 477.3; Comparison of the NMR data with those reported in the literature⁶³ confirmed its identity. *p*-Tolyl 2,3,4,6-tetra-*O*-acetyl-1-thio- β -D-galactopyranoside S8 (11.5 g, 25.3 mmol) was dissolved in a mixture of CH₂Cl₂/MeOH (100 mL/70 mL) and 5.14 M NaOMe (2.4 mL, 12.7 mmol) was added. The mixture was stirred at room temperature for 6 h under N₂ and then was neutralized with Amberlite IR-120 and concentrated to dryness. Silica gel column chromatography (10:1 CH₂Cl₂–MeOH) afforded *p*-tolyl 1-thio- β -D-galactopyranoside (S9) as white solid (7.2 g, quantitative). ¹H-NMR (600 MHz, CD₃OD): δ 2.28 (s, 3H, SPhCH₃), 3.47 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 3.0$ Hz, H-3), 3.51 (t, 1H, $J = 6.6$ Hz, H-5), 3.55 (t, 1H, $J = 9.6$ Hz, H-2), 3.67–3.75 (m, 2H, H-6a, H-6b), 3.87 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4), 4.49 (d, 1H, $J_{1,2} = 9.6$ Hz, H-1), 7.05–7.12 (m, 2H), 7.40–7.47 (m, 2H); ¹³C-NMR (150 MHz, CD₃OD): δ 19.9, 61.4, 69.2, 69.8, 75.1, 79.4, 89.5, 129.4, 130.9, 131.7, 137.2. ESI-MS [M+Na]⁺ C₁₃H₁₈NaO₅S calcd 309.1, obsd 309.1. *p*-Tolyl 1-thio- β -D-galactopyranoside S9 (3 g, 10.4 mmol) and dibutyltin oxide (2.6 g, 10.4 mmol) were put into MeOH (45 mL). The mixture was heated at reflux for 2 hours and then concentrated to dryness. DMF (30 mL) was added to the resulting residue, *p*-methoxy benzyl chloride (PMBCl, 1.5 mL, 10.4 mmol) and CsF (1.67 g, 10.4 mmol), which was then stirred under N₂ at 50 °C for 2 days and concentrated to dryness. Silica gel column chromatography (1:2 Hexanes–EtOAc) afforded *p*-tolyl 3-*O*-*p*-methoxybenzyl-1-thio- β -D-galactopyranoside (S10) as white solid (2.34 g, 55% for two steps). ¹H-NMR (600 MHz, CD₃OD): δ 2.20 (s, 3H, SPhCH₃), 3.27 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 3.0$ Hz, H-3), 3.35–3.38 (m, 1H, H-5), 3.58–3.65 (m, 3H, $J_{1,2} = 10.2$ Hz, H-2, H-6a, H-6b), 3.67 (s, 3H, OCH₃), 3.94 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4), 4.41 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 4.51, 4.58 (2d, 2H, $J = 11.4$ Hz, CH₂PhOCH₃), 6.72–6.82 (m, 2H), 6.96–7.05 (m, 2H), 7.20–7.28 (m, 2H), 7.30–7.38 (m, 2H); ¹³C-NMR (100 MHz, CD₃OD): δ 21.3, 55.76, 55.81, 62.7, 67.6, 70.3, 72.5, 80.5, 83.5, 90.8, 114.8, 130.64, 130.68, 130.8, 130.9, 131.9, 132.1, 133.1, 133.2, 138.6, 160.9. ESI-MS [M+Na]⁺ C₂₁H₂₆NaO₆S calcd 429.2, obsd 429.3. *p*-Tolyl 3-*O*-*p*-methoxybenzyl-1-thio- β -D-galactopyranoside S10 (3.4 g, 8.36 mmol) was dissolved in DMF (50 mL) and the solution was cooled to 0 °C. NaH (1.34 g, 60% NaH in mineral oil, 33.44 mmol) was added in portions, followed by addition of BnBr (4 mL, 33.44 mmol). The mixture was stirred at room temperature under N₂ overnight and then diluted with EtOAc (250 mL). The mixture was washed with saturated NaHCO₃, water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (8:1 Hexanes–EtOAc) afforded

compound **14** *p*-tolyl 2,4,6-tri-*O*-benzyl-3-*O*-*p*-methoxybenzyl-1-thio- β -*D*-galactopyranoside as white solid (4.5 g, 80%); $[\alpha]_D^{+3.2}$ ($c = 1$, CH_2Cl_2); $^1\text{H-NMR}$ (600 MHz, CDCl_3): δ 2.27 (s, 3H, SPhCH_3), 3.56–3.65 (m, 4H, H-3, H-5, H-6a, H-6b), 3.77 (s, 3H, OCH_3), 3.87 (t, 1H, $J = 9.6$ Hz, H-2), 3.93 (d, 1H, $J_{3,4} = 2.4$ Hz, H-4), 4.40, 4.45, 4.58, 4.62, 4.65, 4.72, 4.78, 4.95 (8d, 8H, $J = 12.0$ Hz, $\text{CH}_2\text{PhOCH}_3$, CH_2Ph), 4.58 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 6.78–6.88 (m, 2H), 6.94–7.02 (m, 2H), 7.24–7.34 (m, 15H, aromatic), 7.35–7.45 (m, 2H), 7.40–7.49 (m, 2H); $^{13}\text{C-NMR}$ (150 MHz, CDCl_3): δ 21.4, 55.5, 69.1, 72.7, 73.8, 73.9, 74.7, 75.9, 77.5, 84.2, 88.3, 114.1, 127.7, 127.96, 128.04, 128.1, 128.2, 128.4, 128.57, 128.59, 128.68, 129.5, 129.8, 130.5, 130.7, 132.5, 137.4, 138.2, 138.7, 139.1, 159.5. ESI-MS $[\text{M}+\text{Na}]^+$ $\text{C}_{42}\text{H}_{44}\text{NaO}_6\text{S}$ calcd 699.3, obsd 699.5.

Compound **14** (0.3g, 0.44 mmol) was dissolved in a mixture of $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ (2.9 mL/0.15 mL) and the solution was cooled to 0 °C. 2,3-Dichloro 5,6-dicyano-1,4-benzoquinone (DDQ, 0.12 g, 0.53 mmol) was added and the mixture was stirred at room temperature for 3 h. The mixture was filtered, diluted with CH_2Cl_2 (30 mL) and the organic phase was washed with H_2O until the solution became colorless. Silica gel column chromatography (4:1 Hexanes–EtOAc) afforded compound **19** as white solid (0.21 g, 85%); $[\alpha]_D -3.9$ ($c = 3.3$, CH_2Cl_2); $^1\text{H-NMR}$ (600 MHz, CDCl_3): δ 2.21 (d, 1H, $J = 5.4$ Hz, OH), 2.30 (s, 3H, SPhCH_3), 3.63–3.68 (m, 5H, H-2, H-3, H-5, H-6a, H-6b), 3.89 (d, 1H, $J_{3,4} = 2.4$ Hz, H-4), 4.44, 4.50 (2d, 2H, $J = 12.0$ Hz, CH_2Ph), 4.56 (d, 1H, $J_{1,2} = 9.0$ Hz, H-1), 4.64 (d, 2H, $J = 12.0$ Hz, CH_2Ph), 4.73, 4.90 (2d, 2H, $J = 12.0$ Hz, CH_2Ph), 6.98–7.08 (m, 2H), 7.28–7.37 (m, 15H), 7.42–7.52 (m, 2H); $^{13}\text{C-NMR}$ (150 MHz, CDCl_3): δ 21.3, 68.8, 73.7, 75.1, 75.4, 75.9, 76.2, 77.5, 78.5, 87.9, 127.9, 127.98, 128.03, 128.05, 128.2, 128.53, 128.56, 128.60, 128.7, 129.8, 130.4, 132.2, 137.5, 138.0, 138.3, 138.7; HRMS: $[\text{M}+\text{Na}]^+$ $\text{C}_{34}\text{H}_{36}\text{NaO}_5\text{S}$ calcd 579.2181, obsd 579.2167.

3-Azidopropyl 2,3,6-tri-*O*-benzyl- β -*D*-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -*D*-glucopyranoside (**15**)

D-Lactose (5 g, 13.87 mmol) was dissolved in pyridine (30 mL) and then BzCl (20 mL, 172 mmol) was added at 0 °C. The mixture was stirred at room temperature under N_2 overnight and then diluted with CH_2Cl_2 (400 mL). The mixture was washed with saturated NaHCO_3 , water and then dried over Na_2SO_4 , filtered and concentrated. The resulting residue was dissolved in CH_2Cl_2 (30 mL) and the solution was cooled to –10 °C. HBr in acetic acid (60 mL, 33% w/w, 104 mmol) was added and the mixture was stirred at room temperature under N_2 for 5 hours. The mixture was diluted with CH_2Cl_2 (200 mL) and poured into crushed ice in saturated NaHCO_3 (400 mL). The organic phase was separated and washed again with saturated NaHCO_3 until the pH is about 7 and then dried over Na_2SO_4 , filtered and concentrated. The resulting residue (2 g, 1.76 mmol), 1-bromo propanol (2.3 mL, 26.4 mmol) and freshly activated molecular sieve MS 4 Å (300 mg) was put into a 100 mL round-bottomed flask containing CH_2Cl_2 (20 mL) and the mixture was stirred at room temperature for 30 minutes. AgOTf (0.54 g, 2.11 mmol) was added and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with CH_2Cl_2 (100 mL) and filtered. The filtrate was washed with saturated aqueous NaHCO_3 and H_2O . The organic layer was dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (3:1 Hexanes–EtOAc) afforded compound 3-bromopropyl 2,3,4,6-tetra-*O*-benzoyl- β -*D*-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzoyl- β -*D*-glucopyranoside (S11) as white solid (1.6 g, 65% for 3 steps). $^1\text{H-NMR}$ (600 MHz, CDCl_3): δ 1.96 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}_3$), 3.27 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}_3$), 3.64 (m, 1H, CH_2N_3), 3.73–3.81 (m, 2H, H-5', H-6a'), 3.88–3.98 (m, 3H, H-5, H-6b', CH_2N_3), 4.32 (t, 1H, $J = 9.6$ Hz, H-4), 4.56 (dd, 1H, $J = 4.2, 12.0$ Hz, H-6a), 4.67 (d, 1H, $J = 12.0$ Hz, H-6b), 4.75 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.96 (d, 1H, $J_{1',2'} = 7.8$ Hz, H-1'), 5.45 (dd, 1H, $J_{2',3'} = 10.2$ Hz, $J_{3',4'} = 3.0$ Hz, H-3'), 5.51 (t, 1H, $J = 9.6$ Hz, H-2), 5.78–5.80 (m, 2H, H-2', H-4'), 5.87 (t, 1H, $J = 9.6$ Hz, H-3), 7.14–8.04 (m, 35H, aromatic); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ 30.1, 32.3, 61.1, 62.4, 67.5, 69.9, 71.4, 71.78, 71.82, 72.83, 73.0, 76.0,

101.1, 101.4, 128.3, 128.4, 128.56, 128.63, 128.8, 129.2, 129.4, 129.5, 129.57, 129.62, 129.68, 129.74, 130.0, 133.2, 133.3, 133.4, 133.6, 164.8, 165.2, 165.3, 165.4, 165.5, 165.8. ESI-MS $[M+Na]^+$ $C_{64}H_{55}NaBrO_{18}$ calcd 1213.3, obsd 1213.6. 3-Bromopropyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranoside S11 (1.2 g, 1 mmol) and NaN_3 (0.66 g, 10 mmol) were dissolved in DMF (10 mL). The mixture was stirred at 60 °C for 30 h and then concentrated. The resulting residue was diluted with EtOAc (200 mL), washed with H_2O and then dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (3:1 Hexanes–EtOAc) afforded compound 3-azidopropyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranoside (S12) as white solid (1.04 g, 90%). 1H -NMR (600 MHz, $CDCl_3$): δ 1.72 (m, 2H, $CH_2CH_2CH_2N_3$), 3.18 (m, 2H, $OCH_2CH_2CH_2N_3$), 3.54 (m, 1H, CH_2N_3), 3.71–3.78 (m, 2H, H-5', H-6a'), 3.86–3.95 (m, 3H, H-5, H-6b', CH_2N_3), 4.29 (t, 1H, $J = 9.0$ Hz, H-4), 4.53 (dd, 1H, $J = 4.2, 12.0$ Hz, H-6a), 4.64 (d, 1H, $J = 12.0$ Hz, H-6b), 4.71 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.93 (d, 1H, $J_{1,2'} = 7.8$ Hz, H-1'), 5.43 (dd, 1H, $J_{2,3'} = 10.2$ Hz, $J_{3',4'} = 3.0$ Hz, H-3'), 5.49 (t, 1H, $J = 7.8$ Hz, H-2), 5.75–5.78 (m, 2H, H-2', H-4'), 5.85 (t, 1H, $J = 9.6$ Hz, H-3), 7.14–8.12 (m, 35H, aromatic); ^{13}C -NMR (100 MHz, $CDCl_3$): δ 29.1, 48.0, 61.2, 62.5, 66.8, 67.7, 70.0, 71.5, 71.9, 72.0, 73.0, 73.2, 76.2, 101.2, 101.4, 128.4, 128.67, 128.71, 128.76, 128.82, 128.99, 129.4, 129.6, 129.66, 129.74, 129.77, 129.84, 129.86, 129.93, 130.18, 130.37, 133.40, 133.5, 133.6, 133.8, 133.9, 165.0, 165.4, 165.58, 165.60, 165.8, 166.0. ESI-MS $[M+Na]^+$ $C_{64}H_{55}NaN_3O_{18}$ calcd 1176.4, obsd 1176.8. 3-Azidopropyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranoside S12 (1 g, 0.86 mmol) was dissolved in MeOH (16 mL) and 5.14 M NaOMe (1.67 mL, 8.6 mmol) was added. The mixture was heated at reflux for 6 hours under N_2 and then was neutralized with Amberlite IR-120 until pH is around 7. It was filtered and concentrated to dryness. Silica gel column chromatography (4:1 CH_2Cl_2 –MeOH) afforded 3-azidopropyl β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside (S13) as white solid (0.36 g, 97%). 1H -NMR (600 MHz, CD_3OD): δ 1.85 (m, 2H, $CH_2CH_2CH_2N_3$), 3.23 (t, 1H, $J = 7.8$ Hz, H-2'), 3.38–3.40 (m, 1H, H-5), 3.40–3.58 (m, 7H, H-2, H-3, H-6a, H-3', H-5', $OCH_2CH_2CH_2N_3$), 3.60–3.64 (m, 1H, CH_2N_3), 3.68 (dd, 1H, $J = 4.8, 12.0$ Hz, H-6a'), 3.76 (dd, 1H, $J = 7.8, 11.4$ Hz, H-4), 3.80 (d, 1H, $J_{3',4'} = 3.0$ Hz, H-4'), 3.83 (dd, 1H, $J = 3.6, 12.0$ Hz, H-6b'), 3.88 (dd, 1H, $J = 4.8, 12.0$ Hz, H-6b), 3.92–3.96 (m, 1H, CH_2N_3), 4.27 (d, 1H, $J_{1,2'} = 7.8$ Hz, H-1'), 4.34 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1); ^{13}C -NMR (150 MHz, CD_3OD): δ 29.0, 48.2, 60.7, 61.3, 66.4, 69.1, 71.4, 73.5, 73.6, 75.2, 75.3, 75.9, 79.4, 103.1, 103.9. ESI-MS $[M+Na]^+$ $C_{15}H_{27}NaN_3O_{11}$ calcd 448.2, obsd 448.2. The mixture of 3-azidopropyl β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside S13 (0.5 g, 1.17 mmol), camphorsulfonic acid (0.14 g, 0.59 mmol), benzaldehyde dimethylacetal (0.2 mL, 1.35 mmol) and DMF (3 mL) was stirred at room temperature under N_2 overnight. The mixture was neutralized with solid $NaHCO_3$ (0.98 g, 1.17 mmol) and then concentrated to dryness. Silica gel column chromatography (8:1 CH_2Cl_2 –MeOH) afforded 3-azidopropyl 4,6-*O*-benzylidene- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside⁶⁴ (S14) as white solid (0.49 g, 81%). 1H -NMR (600 MHz, CD_3OD): δ 1.80 (m, 2H, $CH_2CH_2CH_2N_3$), 3.21 (t, 1H, $J = 7.8$ Hz, H-2'), 3.34–3.39 (m, 3H, H-5, $OCH_2CH_2CH_2N_3$), 3.49–3.62 (m, 6H, H-2, H-3, H-6a, H-3', H-5', CH_2N_3), 3.84–3.89 (m, 3H, H-4, H-6b, CH_2N_3), 4.05 (d, 1H, $J = 11.4$ Hz, H-6a'), 4.11–4.13 (m, 2H, H-4', H-6b'), 4.21 (d, 1H, $J_{1,2'} = 7.8$ Hz, H-1'), 4.40 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 5.52 (s, 1H, CHPh), 7.27–7.48 (m, 5H, aromatic); ^{13}C -NMR (100 MHz, CD_3OD): δ 30.3, 49.4, 61.8, 67.7, 68.29, 68.33, 70.3, 71.8, 73.5, 74.8, 76.3, 76.5, 77.3, 80.1, 102.2, 104.4, 104.9, 127.6, 129.2, 130.0, 139.6. ESI-MS $[M+Na]^+$ $C_{22}H_{31}NaN_3O_{11}$ calcd 536.2, obsd 536.3. 3-Azidopropyl 4,6-*O*-benzylidene- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside S14 (2 g, 3.89 mmol) was dissolved in DMF (25 mL) and the solution was cooled to 0 °C. NaH (0.93 g, 60% NaH in mineral oil, 23.34 mmol) was added in portions, followed by addition of BnBr (2.8 mL, 33.44 mmol). The mixture was stirred at room temperature under N_2 for 6 h and then diluted with EtOAc (250 mL). The mixture was washed with saturated aqueous $NaHCO_3$, water and then dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (6:1 Hexanes–EtOAc) afforded 3-azidopropyl 2,3-di-*O*-benzyl-4,6-*O*-benzylidene- β -D-

galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside⁵³ (S15) as white solid (3 g, 80%); $[\alpha]_D +176.4$ (*c*, 0.56, CH₂Cl₂); $[\alpha]_D +16.1$ (*c* = 1, CHCl₃); ¹H-NMR (600 MHz, CDCl₃): δ 1.88 (m, 2H, CH₂CH₂CH₂N₃), 2.93 (s, 1H, H-5'), 3.33–3.39 (m, 4H, H-3, H-5, OCH₂CH₂CH₂N₃), 3.42 (t, 1H, *J* = 7.8 Hz, H-2'), 3.60–3.64 (m, 2H, H-3', CH₂N₃), 3.68–3.70 (d, 1H, *J* = 10.8 Hz, H-6a), 3.74–3.77 (t, 1H, *J* = 7.8 Hz, H-2), 3.84 (d, 1H, *J*_{3,4} = 12.0 Hz, H-4), 3.86–3.89 (dd, 1H, *J*_{5',6a'} = 4.2 Hz, *J*_{6a',6b'} = 10.8 Hz, H-6a'), 3.96–3.98 (m, 2H, H-6b, CH₂N₃), 4.02 (d, 1H, *J*_{3',4'} = 3.0 Hz, H-4'), 4.20 (d, 1H, *J* = 12.0 Hz, H-6b'), 4.32, (d, 1H, *J* = 12.0 Hz, CH₂Ph), 4.36 (d, 1H, *J*_{1',2'} = 7.8 Hz, H-1'), 4.44 (d, 1H, *J*_{1,2} = 7.8 Hz, H-1), 4.54 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 4.72–4.85 (m, 7H, CH₂Ph), 5.19, 5.46 (2d, 2H, *J* = 12.0 Hz, CH₂Ph), 7.17–7.52 (m, 30H, aromatic); ¹³C-NMR (150 MHz, CDCl₃): δ 29.47, 48.56, 66.57, 66.59, 66.78, 68.44, 69.19, 71.85, 73.22, 73.88, 75.33, 75.35, 75.34, 76.07, 77.80, 79.05, 79.86, 82.06, 83.30, 101.61, 103.09, 103.80, 126.81, 127.55, 127.66, 127.70, 127.87, 127.95, 127.99, 128.15, 128.33, 128.38, 128.45, 128.48, 128.59, 128.61, 128.87, 129.10, 138.32, 138.65, 138.72, 138.84, 139.09, 139.13. ESI-MS [M+Na]⁺ C₅₇H₆₁NaN₃O₁₁ calcd 986.4, obsd 986.7. 3-Azidopropyl 2,3-di-*O*-benzyl-4,6-*O*-benzylidene- β -D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside S15 (0.6 g, 0.62 mmol) and NaBH₃CN (0.35 g, 5.58 mmol) were dissolved in THF (15 mL) and cooled to 0 °C. A solution of HCl in ether (2 M, 3 mL) was added and the mixture was stirred at room temperature for 3 hours and then concentrated to dryness. The obtained residue was diluted with CH₂Cl₂ and washed with 10% HCl, water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (3:1 Hexanes–EtOAc) afforded compound **15** as white solid (0.53 g, 89%); $[\alpha]_D +16.1$ (*c* = 1, CHCl₃); ¹H-NMR (600 MHz, CDCl₃): δ 1.86 (m, 2H, CH₂CH₂CH₂N₃), 2.48 (s, 1H, OH), 3.30–3.41 (m, 6H, H-2', H-3, H-5, H-5', OCH₂CH₂CH₂N₃), 3.46–3.49 (dd, 1H, *J*_{5,6a} = 5.4 Hz, *J*_{6a,6b} = 9.6 Hz, H-6a), 3.55–3.70 (m, 5H, H-2, H-3', H-6a', H-6b, CH₂N₃), 3.79–3.81 (dd, 1H, *J*_{5',6a'} = 4.2 Hz, *J*_{6a',6b'} = 10.8 Hz, H-6b'), 3.94–4.01 (m, 3H, H-4, H-4', CH₂N₃), 4.34–4.45 (m, 5H, *J*_{1,2} = 7.8 Hz, *J*_{1',2'} = 8.4 Hz, H-1, H-1', CH₂Ph), 4.54, 4.64, 4.69 (3d, 3H, *J* = 12.0 Hz, CH₂Ph), 4.73–4.79 (m, 4H, CH₂Ph), 4.83, 4.99 (2d, 2H, *J* = 12.0 Hz, CH₂Ph), 7.19–7.39 (m, 30H, aromatic); ¹³C-NMR (150 MHz, CDCl₃): δ 29.6, 48.6, 66.4, 66.8, 68.5, 68.8, 72.3, 73.1, 73.4, 73.8, 75.36, 75.39, 75.6, 75.7, 76.8, 79.7, 81.4, 82.1, 83.2, 89.5, 102.9, 103.9, 127.6, 127.85, 127.88, 127.95, 127.99, 128.09, 128.12, 128.19, 128.26, 128.40, 128.45, 128.61, 128.67, 128.70, 128.80, 138.2, 138.5, 138.6, 138.88, 138.94, 139.4. ESI-MS [M+Na]⁺ C₅₇H₆₃NaN₃O₁₁ calcd 988.5, obsd 988.8;

3-Azidopropyl 2,3-di-*O*-benzoyl-6-*O*-benzyl- β -D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranoside(**21**)

3-Azidopropyl 4,6-*O*-benzylidene- β -D-galactopyranosyl-(1→4)- β -D-glucopyranoside (0.5 g, 0.97 mmol) was dissolved in pyridine (20 mL) and then BzCl (1.1 mL, 9.7 mmol) was added at 0 °C. The mixture was stirred at room temperature under N₂ overnight and then diluted with CH₂Cl₂ (100 mL). The mixture was washed with saturated aqueous solution of NaHCO₃, water and then dried over Na₂SO₄, filtered and concentrated. The mixture of the resulting residue and NaBH₃CN (0.6 g, 9.7 mmol) in THF (20 mL) was cooled to 0 °C and then a solution of HCl in ether (2 M) was added until the solution was acidic. The mixture was stirred at room temperature for 3 hours and then concentrated to dryness. The resulting residue was diluted with CH₂Cl₂ and washed with 10% aqueous HCl, water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound **21** as gel-like solid (0.7 g, 70% for two steps); $[\alpha]_D +47.9$ (*c* = 1, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 1.70 (m, 2H, CH₂CH₂CH₂N₃), 3.01–3.08 (m, 2H, H-6a', H-6b'), 3.12–3.19 (m, 2H, OCH₂CH₂CH₂N₃), 3.45 (t, 1H, *J* = 6.0 Hz, H-5'), 3.48–3.52 (m, 1H, CH₂N₃), 3.81–3.87 (m, 2H, H-5, CH₂N₃), 4.17–4.26 (m, 4H, H-4, H-4', CH₂Ph), 4.42 (dd, 1H, *J* = 4.8, 12.0 Hz, H-6a), 4.60 (dd, 1H, *J* = 1.8, 12.0 Hz, H-6b), 4.65 (d, 1H, *J*_{1,2} = 7.8 Hz, H-1), 4.76 (d, 1H, *J*_{1',2'} = 7.8 Hz, H-1'), 5.12 (dd, 1H, *J*_{2',3'} = 10.5 Hz, *J*_{3',4'} = 3.0 Hz, H-3'), 5.37 (t, 1H, *J* = 7.8 Hz, H-2), 5.69–5.75 (m, 2H, H-3, H-2'), 7.20–8.02 (m, 30H, aromatic); ¹³C-NMR (100

MHz, CDCl₃): δ 29.0, 48.0, 62.5, 66.6, 67.2, 67.5, 70.1, 72.0, 73.1, 73.1, 73.4, 73.5, 74.4, 76.4, 101.0, 101.4, 127.7, 128.0, 128.6, 129.0, 129.2, 129.3, 129.7, 129.81, 129.84, 129.91, 129.93, 129.98, 130.01, 133.29, 133.37, 133.47, 137.8, 165.2, 165.43, 165.45, 165.88, 165.93; HRMS: [M+Na]⁺ C₅₇H₅₃N₃NaO₁₆ calcd 1058.3324, obsd 1058.3315.

3-Azidopropyl 2,4,6-tri-O-benzyl-3-O-*p*-methoxybenzyl- α -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (16)

After the donor **14** (400 mg, 0.59 mmol), acceptor **15** (540 mg, 0.56 mmol) and activated molecular sieve MS-4 Å (500 mg) were stirred for 30 min at room temperature in a mixture solvent of Et₂O (8 mL) and CH₂Cl₂ (16 mL), the mixture was cooled to -78 °C, followed by addition of AgOTf (456 mg, 1.77 mmol) in Et₂O (12 mL). The mixture was vigorously stirred for 10 min and then *p*-TolSCI (93.7 μ L, 0.59 mmol) was added and the reaction mixture was stirred for 2 h from -78 to -40 °C. (See the general procedure for single step pre-activation based glycosylation for precautions) The mixture was concentrated under vacuum to dryness. The resulting residue was diluted with CH₂Cl₂ (100 mL), followed by filtration. The organic phase was washed with saturated aqueous NaHCO₃ and H₂O and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded **16** as gel-like solid (702 mg, 82%); [α]_D +37.3 (*c* = 2.6, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 1.86 (m, 2H, OCH₂CH₂CH₂N₃), 3.15 (dd, 1H, *J* = 4.8, 8.4 Hz, H-6a), 3.28–3.38 (m, 6H, H-2', H-3, H-5, H-5', OCH₂CH₂CH₂N₃), 3.47–3.50 (m, 2H, H-5'', H-6b), 3.55–3.70 (m, 4H, H-2, H-3', H-6a', CH₂N₃), 3.76 (s, 3H, OCH₃), 3.82 (m, 1H, H-6a''), 3.93–3.98 (m, 3H, H-4, H-4', CH₂N₃), 4.02–4.07 (m, 5H, H-2'', H-3'', H-6b', CH₂Ph), 4.17 (dd, 1H, H-4''), 4.21–4.28 (2d, 2H, *J* = 12.0 Hz, CH₂Ph), 4.33–4.36 (m, 4H, *J*_{1',2'} = 7.8 Hz, H-1', H-6b''), CH₂Ph), 4.44–4.52 (m, 5H, *J*_{1,2} = 7.8 Hz, H-1, CH₂Ph), 4.68–4.80 (m, 7H, CH₂Ph), 4.85–4.87 (m, 2H, CH₂Ph), 5.04 (d, 1H, *J*_{1'',2''} = 3.0 Hz, H-1''), 5.07 (d, 1H, CH₂Ph), 6.77–7.46 (m, 49H, aromatic); ¹³C-NMR (150 MHz, CDCl₃): δ 29.5, 48.6, 55.5, 66.7, 67.9, 68.1, 68.4, 69.7, 72.3, 72.4, 73.26, 73.30, 73.4, 73.50, 74.0, 75.0, 75.13, 75.19, 75.3, 75.50, 75.52, 76.7, 77.4, 79.5, 79.7, 81.9, 82.9, 101.1, 103.1, 103.7, 113.8, 127.62, 127.66, 127.68, 127.72, 127.74, 127.76, 127.83, 127.84, 127.86, 127.89, 127.91, 128.11, 128.21, 128.37, 128.40, 128.42, 128.48, 128.50, 128.51, 128.52, 128.54, 128.56, 128.63, 128.80, 129.08, 138.26, 138.59, 138.66, 138.83, 138.86, 138.99, 139.01, 139.20, 139.33, 159.1; HRMS: [M+Na]⁺ C₉₂H₉₉N₃NaO₁₇ calcd 1540.6872, obsd 1540.6831. gHMQC (without ¹H decoupling): ¹J_{C1',H1'} = 169.0 Hz, ¹J_{C1',H1''} = 160.1 Hz, ¹J_{C1,H1} = 160.0 Hz.

3-Azidopropyl 2,4,6-tri-O-benzyl- α -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside(17)

Compound **16** (0.51 g, 0.34 mmol) was dissolved in a mixture of CH₂Cl₂/H₂O (4.9 mL/0.5 mL) and the solution was cooled to 0 °C. DDQ (0.84 g, 0.37 mmol) was added and the mixture was stirred at room temperature for 4 hours. The mixture was filtered, diluted with CH₂Cl₂ (100 mL) and the organic phase was washed with H₂O until the solution became colorless. Silica gel column chromatography (4:1 Hexanes–EtOAc) afforded compound **17** as white solid (0.37 g, 80%). [α]_D +34.6 (*c* = 1, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 1.87 (m, 2H, CH₂CH₂CH₂), 3.17 (dd, 1H, *J* = 4.8, 8.4 Hz, H-6a), 3.27–3.39 (m, 6H, H-2', H-3, H-5, H-5', OCH₂), 3.44–3.62 (m, 6H, H-2, H-3', H-5'', H-6b, H-6a', CH₂N₃), 3.69–3.82 (m, 3H, H-2'', H-6a'', H-6b'), 3.91–4.14 (m, 9H, H-4, H-4', H-4'', H-3'', CH₂N₃, CH₂Ph), 4.34–4.39 (m, 3H, *J*_{1',2'} = 7.8 Hz, H-1', H-6a''), CH₂Ph), 4.45 (d, 1H, *J*_{1,2} = 7.8 Hz, H-1), 4.47–4.54 (m, 4H, CH₂Ph), 4.67–4.84 (m, 8H, CH₂Ph), 5.07 (d, 1H, *J* = 12.0 Hz, CH₂Ph), 5.10 (d, 1H, *J*_{1'',2''} = 3.0 Hz, H-1''), 7.13–7.39 (m, 45H, aromatic); ¹³CNMR (150 MHz, CDCl₃): δ 29.5, 48.6, 66.8, 67.9, 68.0, 68.5, 69.5, 70.3, 72.4, 73.27, 73.33, 73.38, 73.43, 75.1, 75.31, 75.36, 75.47, 75.51, 75.53, 77.2, 77.9, 79.6, 81.8, 81.9, 83.2, 89.5, 99.9, 103.0, 103.8, 127.5, 127.74, 127.76, 127.78, 127.79, 127.85, 127.86, 127.88, 127.92, 127.95, 128.00, 128.02, 128.10, 128.27, 128.34, 128.35, 128.42, 128.44, 128.52, 128.55, 128.56, 128.58, 128.60, 128.71, 128.79, 138.27,

138.48, 138.57, 138.62, 138.82, 138.83, 138.93, 139.02, 139.6; HRMS: $[M+Na]^+$
 $C_{84}H_{91}N_3NaO_{16}$ calcd 1420.6297, obsd 1420.6276.

***p*-Tolyl 2,3,4-tri-*O*-benzyl-1-thio- β -*L*-fucopyranoside (18)**

L-Fucose (10 g, 60.9 mmol) and DMAP (0.72 g, 6.01 mmol) were dissolved in anhydrous pyridine (100 mL) and acetic anhydride (40 mL) was added at room temperature in a period of 30 minutes. The mixture was stirred at room temperature under N_2 overnight and then quenched with ethanol (20 mL) at 0 °C. The mixture was concentrated and the resulting residue was diluted with ethyl acetate (300 mL), washed with water, saturated $NaHCO_3$, 10 % aqueous hydrochloric acid and brine. The organic phase was dried over Na_2SO_4 and then filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded the 1,2,3,4-tetra-*O*-acetyl-*L*-fucopyranoside as white solid (21 g, quantitative, α/β mixtures) with the α isomer (S16) as the major product. 1H -NMR (600 MHz, $CDCl_3$): δ 1.01 (d, 3H, $J_{5,6} = 6.6$ Hz, H-6), 1.86, 1.87, 2.01, 2.04 (4s, 12H, 4 \times COCH₃), 4.15 (m, 1H, H-5), 5.15 (d, 1H, $J_{1,2} = 3.6$ Hz, H-2), 5.16–5.20 (m, 2H, H-3, H-4), 6.18 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1); ^{13}C -NMR (150 MHz, $CDCl_3$): δ 16.0, 20.6, 20.7, 20.8, 21.0, 66.6, 67.3, 67.9, 70.6, 89.9, 169.2, 170.0, 170.2, 170.6. ESI-MS $[M+Na]^+$ $C_{14}H_{20}NaO_9$ calcd 355.1, obsd 355.3. The obtained α/β mixture of 1,2,3,4-tetra-*O*-acetyl-*L*-fucopyranoside (21 g), *p*-toluenethiol (8.32 g, 67 mmol) were dissolved in CH_2Cl_2 (180 mL) and cooled to 0 °C. Boron trifluoride etherate (10.5 mL, 83 mmol) was added dropwise at 0 °C and the mixture was stirred under N_2 at room temperature overnight. The mixture was diluted with CH_2Cl_2 and washed with saturated aqueous $NaHCO_3$ until the pH around 7 and then dried over Na_2SO_4 , filtered and concentrated. The obtained crude product was recrystallized by EtOAc/hexanes to give *p*-tolyl 2,3,4-tri-*O*-acetyl-1-thio- β -*L*-fucopyranoside⁶³ (S17) as white solid (11.6g, 48%). 1H -NMR (600 MHz, $CDCl_3$): δ 1.15 (d, 3H, $J_{5,6} = 6.6$ Hz, H-6), 1.90, 2.01, 2.07 (3s, 9H, 3 \times COCH₃), 2.26 (s, 3H, SPhCH₃), 3.74 (m, 1H, H-5), 4.58 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 4.98 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 3.0$ Hz, H-3), 5.13 (t, 1H, $J = 9.6$ Hz, H-2), 5.18 (d, 1H, $J_{3,4} = 3.0$ Hz, H-4), 7.00–7.09 (m, 2H), 7.30–7.39 (m, 2H); ^{13}C -NMR (150 MHz, $CDCl_3$): δ 16.7, 20.8, 20.9, 21.1, 21.3, 67.5, 70.5, 72.6, 73.2, 86.9, 129.3, 129.8, 133.0, 138.3, 169.6, 170.3, 170.8. ESI-MS $[M+Na]^+$ $C_{19}H_{24}NaO_7S$ calcd 419.1, obsd 419.2. *p*-tolyl 2,3,4-tri-*O*-acetyl-1-thio- β -*L*-fucopyranoside S17 (9.2 g, 23.2 mmol) was dissolved in a mixture of CH_2Cl_2 /MeOH (70 mL /50 mL) and 1 M NaOMe (12 mL, 11.6 mmol) was added at room temperature. The mixture was stirred for 2 h at room temperature under N_2 , neutralized with Amberlite IR-120, concentrated and vacuum dried. The obtained residue (6 g) was dissolved in DMF (100 mL) and cooled to 0 °C. NaH (3.6 g, 60% NaH in mineral oil, 88 mmol) was added in portions, followed by addition of BnBr (10.5 mL, 88 mmol) 30 minutes later. The mixture was stirred at room temperature under N_2 for 2 hours and then diluted with EtOAc (300 mL). The mixture was washed with saturated aqueous solution of $NaHCO_3$, water and then dried over Na_2SO_4 , filtered and concentrated. The obtained crude product was recrystallized by EtOAc/Hexanes to give compound **18**³⁷ as white solid (9.4 g, 75% for two steps); $[\alpha]_D -9.4$ ($c = 1$, CH_2Cl_2); 1H -NMR (600 MHz, $CDCl_3$): δ 1.25 (d, 3H, $J_{5,6} = 6.6$ Hz, H-6), 2.29 (s, 3H, SPhCH₃), 3.50 (m, 1H, H-5), 3.58 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 2.4$ Hz, H-3), 3.62 (d, 1H, $J_{3,4} = 2.4$ Hz, H-4), 3.89 (t, 1H, $J = 9.6$ Hz, H-2), 4.55 (d, 1H, $J_{1,2} = 10.2$ Hz, H-1), 4.66 (d, 1H, $J = 12.0$ Hz, CH_2Ph), 4.72–4.81 (m, 4H, $J = 12.0$ Hz, CH_2Ph), 5.00 (d, 1H, $J = 12.0$ Hz, CH_2Ph), 6.94–7.08 (m, 2H), 7.27–7.40 (m, 15H, aromatic), 7.44–7.56 (m, 2H); ^{13}C -NMR (150 MHz, $CDCl_3$): δ 17.6, 21.4, 73.1, 74.8, 75.8, 76.8, 77.4, 84.8, 88.1, 127.7, 127.8, 127.95, 127.97, 128.2, 128.4, 128.59, 128.62, 128.70, 129.78, 130.7, 132.4, 137.4, 138.6, 138.7, 139.0. ESI-MS $[M+Na]^+$ $C_{34}H_{36}NaO_4S$ calcd 563.2, obsd 563.5.

3-Azidopropyl 2,3,4-tri-*O*-benzyl- α -*L*-fucopyranosyl-(1 \rightarrow 2)-3,4,6-tri-*O*-benzyl- β -*D*-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy- β -*D*-galactopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- α -*D*-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -*D*-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -*D*-glucopyranoside (20a) and 3-

Azidopropyl 2,3,4-tri-O-benzyl- α -L-fucopyranosyl-(1 \rightarrow 2)-3,4,6-tri-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 \rightarrow 3)-2,4,6-tri-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (20 β)

After the donor **18** (50 mg, 92.47 μ mol) and freshly activated molecular sieve MS-4 Å (500 mg) were stirred for 30 minutes at room temperature in Et₂O (4 mL), the solution was cooled to -78 °C, followed by addition of AgOTf (72 mg, 277.4 μ mol) in Et₂O (1.5 mL). The mixture was stirred for 5 minutes at -78 °C and then *p*-TolSCI (14.7 μ L, 92.47 μ mol) was added into the solution. (See the general procedure for single step pre-activation based glycosylation for precautions) The mixture was vigorously stirred for 5 minutes, followed by addition of a solution of acceptor **13** (77.1 mg, 78.60 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL). The reaction mixture was stirred for 2 hour from -78 to -20 °C and then the mixture was cooled down to -78 °C, followed by addition of AgOTf (24 mg, 92.47 μ mol) in Et₂O (1 mL). The mixture was stirred for 10 minutes at -78 °C and then *p*-TolSCI (12.5 μ L, 78.60 μ mol) was added into the solution. After stirred for 5 minutes, a solution of acceptor **19** (30.9 mg, 55.48 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL) was added slowly along the flask wall into the mixture and the reaction mixture was stirred for 2 h from -78 to -20 °C. The mixture was cooled down again to -78 °C, followed by sequential additions of AgOTf (24 mg, 92.47 μ mol) in Et₂O (1 mL), the last acceptor **15** (35.7 mg, 36.99 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL). The mixture was stirred for 10 minutes at -78 °C and then *p*-TolSCI (12.5 μ L, 78.60 μ mol) was added into the solution. The reaction mixture was stirred for 2 hours from -78 to 10 °C and then was quenched with Et₃N (40 μ L), concentrated under vacuum to dryness. The resulting residue was diluted with CH₂Cl₂ (30 mL), followed by filtration. The organic phase was washed with saturated aqueous solution of NaHCO₃, H₂O and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded 46.6 mg of **20 α** (47%) and 22.4 mg of **20 β** (23%) respectively as colorless gel. For **20 α** : [α]_D -18.0 ($c = 2.4$, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 0.42 (d, 3H, $J = 6.6$ Hz, H-6'''), 1.84 (m, 2H, OCH₂CH₂CH₂N₃), 2.80 (s, 1H), 3.19 (m, 1H), 3.27–3.39 (m, 7H), 3.46–3.68 (m, 11H), 3.76–3.86 (m, 5H), 3.92–4.25 (m, 17H), 4.29–4.59 (m, 18H), 4.64–4.87 (m, 13H), 4.94 (d, 1H, $J_{1'',2''} = 3.0$ Hz, H-1''), 5.06 (d, 1H, $J = 11.4$ Hz), 5.24 (d, 1H, $J = 11.4$ Hz), 5.42 (s, 1H), 5.55 (d, 1H, $J_{1''''',2''''} = 3.6$ Hz, H-1''''), 7.00–7.45 (m, 80H, aromatic); ¹³C-NMR (150 MHz, CDCl₃): δ 16.1, 29.4, 29.9, 48.5, 54.4, 66.2, 66.6, 66.7, 67.7, 68.1, 68.4, 69.0, 69.2, 69.4, 72.0, 72.1, 72.5, 72.7, 72.9, 73.1, 73.22, 73.24, 73.28, 73.57, 73.63, 73.77, 73.9, 74.57, 74.67, 74.76, 74.78, 74.94, 75.13, 75.18, 75.27, 75.4, 76.2, 76.3, 76.8, 77.6, 78.6, 79.2, 79.7, 80.4, 81.5, 81.7, 82.0, 84.1, 95.8, 97.5, 100.8, 101.8, 102.6, 102.7, 102.8, 103.6, 126.6, 127.03, 127.06, 127.24, 127.28, 127.31, 127.41, 127.44, 127.55, 127.61, 127.67, 127.68, 127.70, 127.76, 127.79, 127.81, 127.93, 128.01, 128.02, 128.11, 128.16, 128.18, 128.20, 128.34, 128.38, 128.42, 128.45, 128.50, 128.56, 128.65, 128.68, 128.72, 128.76, 128.77, 129.1, 129.9, 137.9, 138.2, 138.3, 138.44, 138.45, 138.47, 138.67, 138.81, 138.94, 138.99, 139.1, 139.4, 139.7, 139.8, 154.0; HRMS: [M+Na]⁺ C₁₅₄H₁₆₃Cl₃N₄O₃₁ calcd 2692.0265, obsd 2692.0332. gHMQC (without ¹H decoupling): $^1J_{C1''',H1'''} = 171.9$ Hz, $^1J_{C1'',H1''} = 169.8$ Hz, other four $^1J_{C1,H1} = 160.1$ Hz, 160.1 Hz, 162.6 Hz, 162.6 Hz.

For **20 β** : [α]_D -4.2 ($c = 1$, CH₂Cl₂); ¹H-NMR (600 MHz, CDCl₃): δ 0.60 (d, 3H, $J = 6.6$ Hz, H-6'''), 1.85 (m, 2H, OCH₂CH₂CH₂N₃), 3.22–3.63 (m, 21H), 3.66–3.79 (m, 6H), 3.86–3.99 (m, 6H), 4.05–4.24 (m, 7H), 4.28–4.51 (m, 18H), 4.55–4.60 (m, 4H), 4.63–4.79 (m, 8H), 4.85–4.94 (m, 3H), 5.09–5.13 (m, 2H), 5.22 (d, 1H, $J = 12.0$ Hz), 5.49 (s, 1H), 5.55 (d, 1H, $J_{1''''',2''''} = 3.6$ Hz, H-1''''), 6.92–7.43 (m, 80H, aromatic); ¹³C-NMR (150 MHz, CDCl₃): δ 16.4, 29.5, 29.9, 48.5, 54.7, 66.6, 67.1, 68.2, 68.8, 69.0, 69.2, 69.3, 70.0, 72.3, 72.68, 72.74, 73.0, 73.3, 73.67, 73.69, 73.75, 73.80, 73.96, 74.75, 74.99, 75.12, 75.2, 75.4, 75.8, 76.2, 76.3, 76.6, 78.4, 79.3, 79.9, 80.6, 81.4, 81.8, 82.6, 83.2, 83.7, 96.0, 97.4, 101.6, 101.9, 102.8, 103.1, 103.7, 126.8, 126.92, 126.96, 127.1, 127.2, 127.36, 127.40, 127.45, 127.48, 127.51, 127.53,

127.67, 127.69, 127.73, 127.76, 127.83, 127.87, 127.90, 127.93, 128.01, 128.07, 128.10, 128.16, 128.27, 128.28, 128.34, 128.35, 128.38, 128.44, 128.50, 128.52, 128.53, 128.60, 128.64, 128.67, 128.71, 129.2, 138.1, 138.2, 138.3, 138.43, 138.47, 138.51, 138.57, 138.86, 138.88, 138.97, 139.06, 139.24, 139.51, 139.8, 140.0, 154.1; HRMS: $[M+Na]^+$ $C_{154}H_{163}Cl_3N_4NaO_{31}$ calcd 2692.0265, obsd 2692.0254. $^1J_{C1, H1} = 170.9$ Hz, other five $^1J_{C1, H1} = 162.0$ Hz, 162.0 Hz, 162.0 Hz, 162.0 Hz, 159.4 Hz.

Three component one-pot synthesis procedure:

After the donor **18** (50 mg, 92.47 μ mol) and activated molecular sieve MS-4 Å (500 mg) were stirred for 30 minutes at room temperature in Et₂O (6 mL), the solution was cooled to -78 °C, followed by addition of AgOTf (72 mg, 277.4 μ mol) in Et₂O (1.5 mL). The mixture was stirred for 5 minutes at -78 °C and then *p*-TolSCI (14.7 μ L, 92.47 μ mol) was added into the solution. (See the general procedure for single step pre-activation based glycosylation for precautions) The mixture was vigorously stirred for 10 minutes, followed by addition of a solution of acceptor **13** (81.7 mg, 83.22 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL). The reaction mixture was stirred for 2 hours from -78 to -20 °C and then the mixture was cooled down to -78 °C, followed by sequential additions of AgOTf (24 mg, 92.47 μ mol) in Et₂O (1 mL), acceptor **17** (90.5 mg, 64.73 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL). The mixture was stirred for 5 minutes at -78 °C and then *p*-TolSCI (13.2 μ L, 83.22 μ mol) was added into the solution. The reaction mixture was stirred for 3 hours from -78 to 10 °C and then was quenched with Et₃N (40 μ L), concentrated under vacuum to dryness. The resulting residue was diluted with CH₂Cl₂ (30 mL), followed by filtration. The organic phase was washed with saturated aqueous NaHCO₃, H₂O and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded **20a** as colorless gel (128mg, 74%).

3-Azidopropyl α -L-fucopyranosyl-(1→2)- β -D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy- β -D-galactopyranosyl-(1→3)- α -D-galactopyranosyl-(1→4)- β -D-galactopyranosyl-(1→4)- β -D-glucopyranoside (**2**)

The mixture of compound **20a** (0.075g, 0.028 mmol), 1 M NaOH (0.56 mL, 0.56 mmol) and THF (4 mL) was stirred at 50 °C overnight and then concentrated to dryness. The resulting residue was diluted with CH₂Cl₂ (50 mL) and the organic phase was washed by H₂O and then dried over Na₂SO₄, filtered and concentrated to dryness. The resulting residue was dissolved in pyridine (2 mL) and catalytic amount of DMAP was added. Acetic anhydride (0.5 mL, 5.3 mmol) was added dropwise and the mixture was stirred at room temperature under N₂ for 4 hours. The reaction was quenched by adding a few drops of H₂O and then diluted with EtOAc (20 mL). The organic phase was washed with saturated aqueous solution of NaHCO₃, H₂O and then dried over Na₂SO₄, filtered and concentrated to dryness. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded the *N*-acetylation product as white solid. The mixture of the *N*-acetylation product, 1 M of PMe₃ in THF (56 μ L, 0.056 mmol), 0.1 M NaOH (0.5 mL, 0.05 mmol) and THF (3 mL) was stirred at 60 °C under N₂ overnight. The mixture was concentrated and the resulting residue was diluted with CH₂Cl₂ (50 mL). The organic phase was washed with H₂O and then dried over Na₂SO₄, filtered and concentrated to dryness. The resulting residue was purified by quickly passing through a short silica gel column (10:1, CH₂Cl₂–MeOH). The mixture of the obtained solid and Pd(OH)₂ in MeOH/H₂O/HOAc (3 mL/1 mL/1 mL) was stirred under H₂ at room temperature overnight and then filtered. The filtrate was concentrated to dryness under vacuum and then was co-evaporated with H₂O (10 mL) three times to remove the AcOH. The aqueous phase was further washed with CH₂Cl₂ (5 mL \times 3) and EtOAc (5 mL \times 3) and then the aqueous phase was dried under vacuum to afford compound **2** (acetate salt) as white solid (16.2 mg, 50% for three steps). $[\alpha]_D^{25} +27.8$ ($c = 1.4$, H₂O); 1H -NMR (600 MHz, D₂O): δ 1.00 (d, 3H, $J = 6.6$ Hz, H-6'''), 1.74 (s, 3H), 1.79 (m,

2H), 1.83 (s, 3H), 2.95 (t, 2H, $J = 6.6$ Hz), 3.12 (t, 1H, $J = 8.4$ Hz), 3.36–3.89 (m, 32H), 4.02–4.03 (m, 2H), 4.18 (t, 1H, $J = 6.0$ Hz), 4.29 (d, 2H, $J = 7.8$ Hz), 4.32 (d, 1H, $J = 7.8$ Hz), 4.40 (d, 1H, $J = 7.8$ Hz), 4.69 (d, 1H, $J = 3.6$ Hz), 5.02 (d, 1H, $J = 3.6$ Hz); ^{13}C -NMR (150 MHz, D_2O): δ 15.4, 22.3, 23.4, 26.8, 37.7, 51.8, 60.1, 60.5, 61.1, 66.9, 67.9, 68.1, 68.6, 69.2, 69.3, 69.6, 70.2, 71.0, 72.0, 72.2, 73.0, 73.7, 74.5, 74.7, 75.0, 75.2, 75.6, 76.2, 76.4, 77.3, 78.3, 78.8, 99.4, 100.6, 102.2 ($\times 2$), 103.5, 104.1, 174.4; HRMS: $[\text{M}+\text{Na}]^+$ $\text{C}_{41}\text{H}_{72}\text{N}_2\text{NaO}_{30}$ calcd 1095.4068, obsd 1095.4048. $^1\text{J}_{\text{C}1^{\text{m}},\text{H}1^{\text{m}}} = 170.0$ Hz, $^1\text{J}_{\text{C}1^{\text{r}},\text{H}1^{\text{r}}} = 171.2$ Hz, Other four $^1\text{J}_{\text{C}1,\text{H}1} = 162.6$ Hz, 163.9 Hz, 162.4 Hz, 162.4 Hz.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment


We are grateful for financial supports from the University of Toledo, the National Institutes of Health (R01-GM-72667) and the Pardee foundation. We dedicate this work to Prof. Nina Berova, Columbia University, for her guidance and continual encouragements over the years.

References


- Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Clin. Cancer Res 1998;4:295–302. [PubMed: 9516914]
- Hakomori S, Zhang Y. Chem. Biol 1997;4:97–104. [PubMed: 9190292]
- Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO. Int. J. Cancer 1997;73:42–49. [PubMed: 9334808]
- Kannagi R, Levery SB, Ishijamik F, Hakomori S, Schevinsky LH, Knowles BB, Solter D. J. Biol. Chem 1983;258:8934–8942. [PubMed: 6863318]
- Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S. J. Biol. Chem 1984;259:14773–14777. [PubMed: 6501317]
- Gilewske T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang X-F, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ. Proc. Natl. Acad. Sci. U. S. A 2001;98:3270–3275. [PubMed: 11248068]
- Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudrya-shov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ. Proc. Natl. Acad. Sci. U. S. A 2000;97:2719. [PubMed: 10716997]
- Danishefsky SJ, Allen JR. Angew. Chem. Int. Ed 2000;39:836–863.
- Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI. Proc. Natl. Acad. Sci. U. S. A 1999;96:5710. [PubMed: 10318949]
- Park TY, Kim IJ, Hu S, Bilodeau MT, Randolph JT, Kwon O, Danishefsky SJ. J. Am. Chem. Soc 1996;118:11488–11500.
- Bilodeau MT, Park TK, Hu S, Randolph JT, Danishefsky SJ, Livingston PO, Zhang S. J. Am. Chem. Soc 1995;117:7840–7841.
- Allen JR, Allen JG, Zhang X-F, Williams LJ, Zatorski A, Ragupathi G, Livingston PO, Danishefsky SJ. Chem. Eur. J 2000;6:1366–1375.
- Lassaletta JM, Schmidt RR. Liebigs Ann.Chem 1996:1417–1423.
- Zhu T, Boons GJ. Angew. Chem. Int. Ed 1999;38:3495–3497.
- Huang C-Y, Thayer DA, Chang AY, Best M, Hoffmann L, Head S, Wong C-H. Proc. Natl. Acad. Sci. U. S. A 2006;100:15–20. [PubMed: 16373501]
- Wacowich-Sgarbi, S.; Rabuka, D.; Sgarbi, PWM.; Ichikawa, Y. ACS Symposium Series 873; Synthesis of Carbohydrates through Biotechnology. Wang, PG.; Ichikawa, Y., editors. Washington, DC: American Chemical Society; 2004. p. 23-38.
- Burkhart F, Zhang Z, Wacowich-Sgarbi S, Wong C-H. Angew. Chem. Int. Ed 2001;40:1274–1277.

18. Bosse F, Marcauella LA, Seeberger PH. *J. Org. Chem* 2002;67:6659–6670. [PubMed: 12227795]
19. Werz DD, Castagner B, Seeberger PH. *J. Am. Chem. Soc* 2007;129:2770–2771. [PubMed: 17302423]
20. For an example, see: Adinolfi M, Iadonisi A, Ravidá A, Schiattarella M. *J. Org. Chem* 2005;70:5316–5319. [PubMed: 15960539]
21. Tanaka H, Matoba N, Takanishi T. *Chem. Lett* 2005;34:400–401.
22. Huang L, Huang X. *Chem. Eur. J* 2007;13:529–540.
23. Huang L, Wang Z, Li X, Ye X-S, Huang X. *Carbohydr. Res* 2006;341:1669–1679. [PubMed: 16442505]
24. Huang X, Huang L, Wang H, Ye X-S. *Angew. Chem. Int. Ed* 2004;42:5221–5224.
25. Yu B, Yang Z, Cao H. *Curr. Org. Chem* 2005;9:179–194. and references cited therein
26. Pornsuriyasak P, Demchenko AV. *Tetrahedron: Asymmetry* 2005;6:433–439. and references cited therein
27. Kanie, O. *Carbohydrates in Chemistry and Biology*. Ernst, B.; Hart, GW.; Sinay, P., editors. Vol. 1. Weinheim: Wiley-VCH; 2000. p. 407-426.
28. Fraser-Reid B, Wu Z, Udodong UE, Ottosson H. *J. Org. Chem* 1990;55:6068–6070.
29. Koeller KM, Wong C-H. *Chem. Rev* 2000;100:4465–4493. [PubMed: 11749355] and references cited therein
30. Tanaka H, Adachi M, Takahashi T. *Chem. Eur. J* 2005;11:849–862. and references cited therein
31. Tanaka H, Adachi M, Tsukamoto H, Ikeda T, Yamada H, Takahashi T. *Org. Lett* 2002;4:4213–4216. [PubMed: 12443061]
32. Fraser-Reid B, López JC, Gómez AM, Uriel C. *Eur. J. Org. Chem* 2004;2004:1387–1395.
33. Fraser-Reid B, López JC, Radhakrishnan KV, Mach M, Schlueter U, Gomez AM, Uriel C. *J. Am. Chem. Soc* 2002;124:3198–3199. [PubMed: 11916390]
34. Jennings, HJ.; Snood, RK. *Neoglycoconjugates, Preparation and Application*. Lee, YC.; Lee, RT., editors. San Diego: Academic Press; 1994. p. 325
35. Crich D, Sun S. *Tetrahedron* 1998;54:8321–8348.
36. Martichonok V, Whitesides GM. *J. Org. Chem* 1996;61:1702–1706. [PubMed: 11667039]
37. Zhang Z, Ollman IR, Ye X-S, Wischnat R, Baasov T, Wong C-H. *J. Am. Chem. Soc* 1999;121:734–753.
38. Bock K, Pedersen C. *J. Chem. Soc. Perkin Trans* 1974;2:293–297.
39. Demchenko AV. *Synlett* 2003:1225–1240. and references cited therein
40. Tokimoto H, Fujimoto Y, Fukase K, Kusumoto S. *Tetrahedron Asym* 2005;16:441–447.
41. Chiba H, Funasaka S, Mukaiyama T. *Bull. Chem. Soc. Jpn* 2003;76:1629–1644.
42. Adinolfi M, Barone G, Iadonisi A, Schiattarella M. *Tetrahedron Lett* 2002;43:5573–5577.
43. Jona H, Mandai H, Chavasiri W, Takeuchi K, Mukaiyama T. *Bull. Chem. Soc. Jpn* 2002;75:291–309.
44. Demchenko AV, Stauch T, Boons G-J. *Synlett* 1997:818–819.
45. Schmidt RR, Behrendt M, Toepfer A. *Synlett* 1990:694–696.
46. Kamath VP, Yeske RE, Gregson JM, Ratcliffe RM, Fang YR, Palcic MM. *Carbohydr. Res* 2004;339:1141–1146. [PubMed: 15063203] and references cited therein
47. Chen L, Zhao X-E, Lai D, Song Z, Kong F. *Carbohydr. Res* 2006;341:1174–1180. [PubMed: 16630600] and references cited therein
48. Hsieh S-Y, Jan M-D, Patkar LN, Chen C-T, Lin C-C. *Carbohydr. Res* 2005;340:49–57. [PubMed: 15620666]
49. Wang C, Li Q, Wang H, Zhang L, Ye X-S. *Tetrahedron* 2006;62:11657–11662.
50. Dohi H, Nishida Y, Takeda T, Kobayashi K. *Carbohydr. Res* 2002;337:983–989. [PubMed: 12039538]
51. Bhattacharyya S, Magnusson BG, Wellmar U, Nilsson UJ. *J. Chem. Soc. Perkin Trans* 2001;1:886–890.
52. Sarkar AK, Matta KL. *Carbohydr. Res* 1992;233:245–250. [PubMed: 1344884]
53. Pornsuriyasak P, Demchenko AV. *Carbohydr. Res* 2006;341:1458–1466. [PubMed: 16643871]


54. Crich D, Smith M, Yao Q, Picione J. *Synthesis* 2001:323–326.
55. To determine the configuration of newly formed glycosyl bonds, we once isolated the intermediate oligosaccharides during one-pot synthesis and confirmed the linkages via NMR analysis.
56. Plante OJ, Palmacci ER, Seeberger PH. *Science* 2001;291:1523–1527. [PubMed: 11222853]
57. Li J, Wang J, Czyryca PG, Chang H, Orsak TW, Evanson R, Chang C-WT. *Org. Lett* 2004;6:1381–1384. [PubMed: 15101747]
58. Cheshev PE, Khatuntseva EA, Gerbst AG, Tsvetkov YE, Shashkov AS, Nifantiev NE. *Russ. J. Bioorg. Chem* 2003;29:372–381.
59. Mong TK-K, Lee H-K, Duron SG, Wong C-H. *Proc. Natl. Acad. Sci. U. S. A* 2003;100:797–802. [PubMed: 12552090]
60. Nyffeler PT, Liang C-H, Koeller KM, Wong C-H. *J. Am. Chem. Soc* 2002;124:10773–10778. [PubMed: 12207533]
61. Luening B, Norberg T, Tejbrant J. *Glycoconj. J* 1989;6:5–19. [PubMed: 2535477]
62. Lee J-C, Wu C-Y, Apon JV, Siuzdak G, Wong CH. *Angew. Chem. Int. Ed* 2006;45:2753–2757.
63. Tai C-A, Kulkarni SS, Hung S-C. *J. Org. Chem* 2003;68:8719–8722. [PubMed: 14575510]
64. Yang Z-Q, Puffer EB, Pontrello JK, Kiessling LL. *Carbohydr. Res* 2002;337:1605–1613. [PubMed: 12423961]



Scheme 1.



Scheme 2.



Scheme 3.

Table 1Evaluation of building blocks for **BC** disaccharide synthesis.

Donor (1 eq) + AgOTf $\xrightarrow[2) \text{ acceptor (0.9 eq)}]{1) p\text{-TolSCl, } -78 \text{ }^\circ\text{C}}$ Product			
Entry #	Donor	Acceptor	Product (yield)
1	3	4	-
2	7	4	9 (10 %) ^a
3	8	4	10 (30 %) ^a
4	8	6	11 (30 %) ^a
5	7	5	12β (50 – 70%) ^a
			12α (10 – 20%) ^a
6	8	6	12β (72 %) ^b

[a] AgOTf was added as a solution in diethyl ether to donor dissolved in dichloromethane. Ratio of diethyl ether to dichloromethane is 1:2

[b] AgOTf was added as a solution in acetonitrile to donor dissolved in dichloromethane. Ratio of acetonitrile to dichloromethane is 1:20.